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Zusammenfassung 
Die Lysin-Methylierung von Histonen ist ein epigenetischer Mechanismus, der an der 
Regulation vieler biologischer Prozesse beteiligt ist. In den letzten Jahren hat das Interesse an 
der Lysin-Methylierung von Proteinen deutlich zugenommen, da eine Vielzahl von Protein-
Lysin-Methyltransferasen (PKMTs) und Lysin-Methylierungsstellen in den Genomen und 
Proteomen von verschiedenen Organismen identifiziert wurden. Zusätzlich wurden auch 
Nicht-Histon-Proteine als mögliche Substrate für PKMTs entdeckt. Diese rasante 
Entwicklung hat die Lysin-Methylierung und deren Verständnis in den Mittelpunkt der 
Forschung gerückt. Um unser Wissen über die Lysin-Methylierung weiter zu verbessern, ist 
es wichtig die spezifischen Lysin Methylierungsstellen mit den verantwortlichen PKMTs in 
Verbindung zu bringen und das gesamte Substrat-Spektrum von PKMTs zu untersuchen. In 
dieser Arbeit wurde eine Substratspezifitäts-Analyse durchgeführt, um dieser 
Herausforderung gerecht zu werden. Es wurde gezeigt, dass die Methylierung von 
Peptidarrays ein guter Ansatz ist, um die Substratpräferenz von PKMTs zu analysieren und 
um geringfügige Unterschiede zwischen verwandten Enzymen mit der gleichen 
Gesamtspezifität zu identifizieren. Des Weiteren wurde gezeigt, dass die Substratspezifitäts-
Analyse für die Identifizierung neuer Substrate von Nutzen ist, was in der vorliegenden Arbeit 
für SUV4-20H1, SUV4-20H2, MLL1 und MLL3 erfolgreich nachgewiesen wurde. 
In vitro Methylierungsexperimente haben gezeigt, dass SUV4-20H1 und SUV4-20H2 unter 
der Verwendung von monomethyliertem H4K20 als Substrat eine Dimethylierung von 
H4K20 katalysieren. SUV4-20H1 und SUV4-20H2 haben ein überlappendes Sequenzmotiv, 
wobei SUV4-20H2 eine geringere Spezifität aufweist. Dieses Ergebnis wurde durch die 
Identifizierung eines neuartigen Nicht-Histon-Substrats von SUV4-20H1 und von drei Nicht-
Histon-Substraten für SUV4-20H2 bestätigt. 
MLL1 und MLL3 sind H3K4-Methyltransferasen, aber sie gehören zu verschiedenen MLL-
Unterfamilien. MLL1 katalysiert die H3K4-Trimethylierung an Promotoren von 
Entwicklungsgenen, während MLL3 die Monomethylierung von H3K4 an Enhancern 
katalysiert. MLL1 und MLL3 sind beide Teil eines Multiproteinkomplexes, der unter 
anderem aus WDR5, RBBP5 und ASH2L besteht. Die Substratspezifitäts-Analyse von MLL1 
hat gezeigt, dass MLL1 neben den Aminosäuren der ursprünglichen Sequenzen von H3 auch 
mehrere andere Aminosäuren an zahlreichen Stellen der Zielsequenz toleriert. Auf 
Proteinebene wurden zwei neue Substrate (TICRR und ZNF862) von MLL1 methyliert. Der 
Vergleich der relativen Aktivität hat gezeigt, dass das H3 Protein das bevorzugte Substrat in 
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Abwesenheit der Komplexpartner war, wobei ZNF862 in Gegenwart von WRA bevorzugt 
wurde. Letztendlich haben die Ergebnisse gezeigt, dass sich die Substratspezifität von MLL3-
WRA geringfügig von MLL1 unterscheidet, was darauf hindeutet, dass MLL3-WRA und 
MLL1 unterschiedliche Nicht-Histon-Substrate erkennen können. 
In mehreren Publikationen wurde über die Zuordung von PKMTs und methylierte Histon- 
und Nicht-Histon-Substratproteine berichtet, deren Ergebnisse jedoch fragwürdig sind. Dies 
könnte zu einer falschen Interpretation biologischer Prozesse und zur Irreführung von 
Folgeuntersuchungen führen. In dieser Arbeit wurde anhand von zwei Beispielen gezeigt, 
dass die Substratspezifitäts-Analyse verwendet werden kann, um problematische 
Zuordnungen zwischen PKMT und Methylierungsereignis zu identifizieren, welche 
experimentell untersucht werden müssen, um die veröffentlichten Ergebnisse zu überprüfen. 
Vougiouklakis und Mitarbeiter berichteten 2015, dass K302 und K361 von ERK1 durch 
SUV4-20H1 methyliert würden. Allerdings passen diese Methylierungsstellen nicht zum 
Spezifitätsprofil von SUV4-20H1. Tatsächlich konnte keine Methylierung von ERK1 durch 
SUV4-20H1 oder SUV4-20H2 auf Peptid- und Protein-Ebene nachgewiesen werden, obwohl 
Positivkontrollen die erwartete Methylierung aufweisen. Die Arbeitsgruppe um Dhami 
berichtete 2013, dass das Numb Protein durch SET8 an K158 und K163 methyliert wird, was 
wiederum nicht mit den Spezifitätsergebnissen von SET8 übereinstimmt. In dieser Arbeit 
wurde die Methylierung von Numb auf Peptid- und Proteinebene unter der Verwendung von 
rekombinantem SET8 (aufgereinigt aus E.coli oder HEK293-Zellen) untersucht. In beiden 
Fällen konnte keine Methylierung von Numb beobachtet werden. Diese Ergebnisse deuten 
darauf hin, dass diese Zuordnungen zwischen Methylierungssubstraten und PKMTs 
wahrscheinlich nicht richtig sind. 
In Genom- und Transkriptom Sequenzierungsprojekten wurden häufig auftretende somatische 
Mutationen in epigenetischen Enzymen gefunden, die zur Krebsentwicklung führen. 
Somatische Krebsmutationen können „loss-of-function“ oder „gain-of-function“ Effekte auf 
die enzymatischen Eigenschaften von PKMTs haben. Insbesondere die „gain-of-function“ 
Effekte stellen für das Verständnis ihrer Rolle bei der Krebsentstehung eine Herausforderung 
dar. In dieser Arbeit wurden die Effekte von somatischen Krebsmutationen analysiert, die in 
der SET-Domäne von MLL1 und MLL3 gefunden wurden. Vier somatische Krebsmutationen 
von MLL1 und drei von MLL3 wurden aufgrund ihrer Position in der Nähe der 
Bindungsstellen von AdoMet, Peptid oder den Interaktionspartnern ausgewählt. Die 
Untersuchung der somatischen Krebsmutationen in MLL1 und MLL3 hat gezeigt, dass jede 
XIII
spezifische Mutation einen speziellen Effekt auf die enzymatische Aktivität, die Produkt- oder 
Substratspezifität und den prinzipiellen regulatorischen Mechanismus hat. Das bedeutet, dass 
für jede Mutante spezifische und detaillierte experimentelle Untersuchungen erforderlich sind, 
um ihre karzinogene Wirkung zu verstehen. Darüber hinaus haben Inhibitorstudien gezeigt, 
dass jede Mutante experimentell untersucht werden muss, um die Entwicklung von 
mutationsspezifischen therapeutischen Strategien zu ermöglichen. 
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Abstract 
Histone lysine methylation is an epigenetic mechanism that is involved in the regulation of 
many biological processes. Over the last decade, the global interest in protein lysine 
methylation events increased drastically, because several protein lysine methyltransferases 
(PKMTs) and lysine methylation sites were identified in the genomes and proteomes of many 
organisms also including non-histone proteins functioning as substrates for PKMTs. The fast 
development of this field has moved the understanding of the biological outcome of lysine 
methylation into the center of research. Most urgently, it is necessary to improve our 
knowledge about lysine methylation by connecting specific target sites with the responsible 
PKMT and identifying the full substrate spectrum of PKMTs. In this thesis substrate 
specificity analysis was performed to tackle this challenge. It was shown that methylation of 
substrate specificity arrays is a good approach to analyze the substrate preference of PKMTs 
and identify subtle differences between related enzymes with same overall specificity. 
Furthermore, substrate specificity analysis was shown to be useful for the identification of 
novel substrates, which was successfully demonstrated for SUV4-20H1, SUV4-20H2, MLL1 
and MLL3 in the present study.  
In vitro methylation experiments indicated that SUV4-20H1 and SUV4-20H2 introduce 
dimethylation on H4K20 using monomethylated H4K20 as substrate. SUV4-20H1 and 
SUV4-20H2 have an overlapping sequence motif, but SUV4-20H2 is less specific. This result 
was supported by the identification of one novel non-histone substrate for SUV4-20H1 and 
three non-histone targets for SUV4-20H2. 
MLL1 and MLL3 are H3K4 methyltransferases, but they belong to different MLL 
subfamilies. MLL1 catalyzes H3K4 trimethylation at promotors of developmental genes, 
whereas MLL3 introduces H3K4 monomethylation at enhancers. MLL1 and MLL3 are parts 
of related multi protein complexes also containing WDR5, RBBP5 and ASH2L. Substrate 
specificity analysis of MLL1 showed that it accepts several other residues at many positions 
of the target sequence, in addition to the residues in the original sequences of H3. At the 
protein level two novel substrates (TICRR and ZNF862) were methylated by MLL1. 
Comparison of the relative activity showed that the H3 protein was the best target in the 
absence of complex partners, but ZNF862 was preferred in presence of WRA. Finally, my 
data indicate that the substrate specificity of MLL3-WRA differed slightly from MLL1, 
suggesting that they may have different non-histone substrates. 
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In several publications, assignments between PKMTs and methylated histone or non-histone 
target sites have been reported, but in some cases the data are questionable. This could lead to 
wrong interpretation of biological processes and misleading of follow-up studies. It has been 
shown for two examples in this study, that substrate specificity analysis can be used to 
identify problematic assignments between PKMT and methylation events, which need to be 
studied experimentally to confirm the published findings. 
Vougiouklakis et al. (2015) reported that SUV4-20H1 methylates ERK1 at K302 and K361, 
but these target sites do not fit to the specificity profile of SUV4-20H1. Indeed, I could not 
detect methylation of ERK1 by SUV4-20H1 or SUV4-20H2 at peptide and protein level 
although positive controls showed the expected methylation. Dhami et al. (2013) reported that 
Numb protein is methylated by SET8 at K158 and K163, which was not in agreement with 
the specificity data of SET8. In this thesis, Numb peptide and protein methylation was studied 
using recombinant SET8 purified from E.coli or HEK293 cells. In both cases, no methylation 
of Numb could be observed. These data suggest that these assignments of methylation 
substrates and PKMTs are likely not correct. 
Whole genome and whole transcriptome sequencing projects have frequently found somatic 
mutations in epigenetic enzymes in cancers. Somatic cancer mutations can have loss-of-
function or gain-of-function effects on the enzymatic properties of PKMTs. Especially gain-
of-function effects are a challenge in understanding their role in carcinogenesis. In this study, 
the effects of somatic cancer mutations found in the SET domain of MLL1 and MLL3 were 
analyzed. Four somatic cancer mutations of MLL1 and three of MLL3 were selected for 
analysis on the basis of their location close to binding sites of AdoMet, peptide or the 
interaction partners. The investigation of somatic cancer mutations in MLL1 and MLL3 
indicated that each specific mutation has its unique effect on the enzymatic activity, product 
or substrate specificity and principle regulatory mechanism indicating that each mutant needs 
specific in depth experimental investigation in order to understand its carcinogenic effect. 
Moreover, inhibitor studies demonstrated that each mutant needs to be experimentally studied 
to allow for the development of mutation specific therapeutic strategies. 
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11. Introduction 
1.1. Epigenetics 
In 1942, Waddington introduced an influential definition of the research field of 
“Epigenetics”. He defined epigenetics as “the branch of biology, which studies the causal 
interactions between genes and their products that bring the phenotype into being” 
(Waddington 2012). During the past years, research in epigenetics has gained more and more 
importance and also the definition of the field has changed over time. Riggs and colleagues 
described epigenetics as “the study of mitotically and/or meiotically heritable changes in gene 
function that cannot be explained by changes in DNA sequence” (Riggs, 1996). Epigenetic 
mechanisms, including DNA methylation, histone modification and noncoding RNA 
molecules, alter the structure of chromatin and thus regulate the expression of specific genes. 
The epigenetic phenomenon describes the differentiation of cells into different cell types and 
the specialization into multicellular organism as well as the adaptation of cells and organism 
to environmental changes (Goldberg et al. 2007). The involvement of epigenetic mechanisms 
in the development of diseases, such as cancer, highlights the importance of epigenetics. In 
the past, cancers were mainly connected with mutations of oncogenes and tumor suppressor 
genes. Today it is known that mutations in the genome can influence enzymatic properties of 
epigenetic proteins that lead to changes in the readout of the genome. Stephen Baylin was one 
of the first researchers who identified epigenetic silencing of a tumor suppressor gene by 
DNA hypermethylation, which causes decreased protein expression and results in tumor 
growth (Brower 2011; Portela & Esteller 2010). Furthermore, environmental effects, like 
smoking, fatty food, etc. can influence the methylation level of genes and by this impact the 
development of cancers (Brower 2011). Hence, the participation of epigenetics in the 
development of cancers provides a new paradigm for cancer therapy and prevention, which is 
a topic of high interest these days.  
1.2. Chromatin structure 
In eukaryotic cells, chromatin is a highly organized polymer which represents the 
physiological template of all genetic information. The basic repeating unit of chromatin is the 
nucleosome, which consists of a histone octamer containing duplicates of each core histone 
protein, H3, H4, H2A and H2B, and a 147 bp long DNA fragment wrapped 1.7 times around 
the histone core (Luger et al. 1997; Kouzarides 2007). Adjacent nucleosomes are connected to 
each other by a 20-60 bp long linker DNA visualized as “beads-on-string” structure on 
isolated chromatin sample in electron microscopy images (Trojer & Reinberg 2007). 
2However, this first step of compaction is not enough to pack the 2 meter long human DNA 
filament into the cell nucleus. For further compaction, a linker histone of the H1 type binds to 
the linker DNA and nucleosomes, protecting the negative charge between adjacent 
nucleosomes and establishing the so-called “30 nm fiber”. The 30 nm fiber is a helix of 6 to 7 
nucleosomes per 11 nm with a diameter of 30 nm (Jenuwein & Allis 2001; Luger et al. 1997; 
Song et al. 2014). This and further levels of compaction ultimately lead to the most condensed 
form of DNA called chromosomes (Figure 1) (Trojer & Reinberg 2007; Margueron et al. 
2005). 
Figure 1: Schematic representation of eukaryotic DNA located in the cell nucleus. In the nucleus of a eukaryotic cell, the 
DNA is compacted due to the interaction of the histone proteins. Duplicates of the core histone proteins H3, H4, H2A and 
H2B form the nucleosome, which is surrounded by the DNA. The unstructured C-and N-terminal tails of the core histone 
proteins are protruding from the nucleosomes and are subject to numerous posttranslational modifications, like H3K4, 
H3K79 methylation or H2B monoubiquitination represented as examples in this figure. Further compactions lead to the 
formation of the highly condensed chromosome. The figure is taken from (Shilatifard 2012). 
The core histone proteins are evolutionary conserved and form a globular structure with 
unstructured C- and N-terminal tails protruding from the nucleosomes (Jenuwein & Allis 
2001). Both tails are subject to several posttranslational modifications (PTM) which regulate 
the chromatin structure and dynamics together with DNA methylation and the presence of 
non-coding RNA (Kouzarides 2007; Strahl & Allis 2000). Some parts of the chromatin, called 
euchromatin, are loosely packed and transcriptionally active, whereas heterochromatin, is 
more densely packed and contains inactive genes (Jenuwein & Allis 2001). Altogether the 
epigenetic marks affect a large number of very important cellular processes including 
transcription, DNA replication, DNA repair and genomic stability (Gelato & Fischle 2008). 
31.3. DNA methylation 
DNA methylation is an important epigenetic process that plays a critical role in gene 
regulation during embryogenesis and gametogenesis (Goll & Bestor 2005). DNA 
methyltransferases (DNMTs) catalyze the transfer of a methyl group from the cofactor S-
adenosyl-L-methionine (AdoMet) to the C5 position of cytosine residues in CpG 
dinucleotides, generating 5-methylcytosine and S-adenosyl-L-homocysteine (AdoHcy) 
(Jeltsch & Jurkowska 2016; Jurkowska et al. 2011). CpG sites are often found in CpG islands, 
regions with a high density of CpG dinucleotides. An enrichment of methylated CpG islands 
is often discovered at noncoding regions like centromeric heterochromatin, imprinted genes or 
transposons to silence the expression of these elements and prevent genomic instability. 
Conversely, CpG islands are often unmethylated in regulatory elements like promotors and 
enhancers of specific genes (Jin & Robertson 2013). In mammals, four different DNMTs are 
present, DNMT1, DNMT3A, DNMT3B and DNMT3L (Jeltsch & Jurkowska 2016). 
DNMT3A and DNMT3B are so-called “de novo methyltransferases” (Mtases) and are 
responsible for setting the initial methylation pattern in early embryonic development. 
DNMT3L is catalytically inactive, but essential for the catalytic activity and genomic 
specificity of DNMT3A and DNMT3B. After DNA replication, fully methylated DNA is 
converted to hemimethylated DNA. The so-called maintenance DNA methyltransferase 
DNMT1 is responsible for remethylation of the DNA to retain inherit methylation pattern 
(Portela & Esteller 2010; Jurkowska et al. 2011). It has been reported that changes in the 
DNA methylation pattern contribute to the development of diseases, like breast, prostate and 
colorectal cancer (Miremadi et al. 2007; Portela & Esteller 2010). 
1.4. Noncoding RNA 
High-throughput genome wide studies have shown that only ~ 2% of the transcribed human 
genome encodes for proteins, whereas the rest is transcribed as noncoding RNA (Amaral et al. 
2008). Noncoding RNA (ncRNA) molecules are important for the epigenetic regulation of 
gene expression and chromatin remodeling (Bernstein & Allis 2005). They are categorized 
into small and long ncRNAs. Small ncRNAs include micro RNAs (miRNAs), piwi-
interacting RNAs (piRNAs), and small interfering RNAs (siRNAs) (Kaikkonen et al. 2011). 
In 1998, Fire discovered the RNA interference (RNAi) process in Caenorhabditis elegans, 
which describes the phenomenon that double stranded RNA (dsRNA) can trigger gene 
silencing (Fagard & Vaucheret 2000). Up to date this is one of the best-studied post-
transcriptional gene silencing mechanism based on noncoding RNAs. Beside RNA silencing, 
which is used in many organism to fight against infections with RNA viruses or transposable 
4elements, noncoding RNAs play a role in heterochromatin formation, histone modification 
and DNA methylation by the recruitment of transcription factors, chromatin modifying 
complexes or by direct interaction with homologous RNA or DNA strands (Waterhouse et al. 
2001; Gitlin & Andino 2003; Bonasio et al. 2010; Chen 2016). 
1.5. Posttranslational modifications of histone proteins
Beside DNA methylation and noncoding RNAs, posttranslational modifications (PTM) of 
histone proteins play a key role in the regulation of chromatin and thereby influence many 
cellular processes, like transcription, DNA repair, replication and recombination (Bannister & 
Kouzarides 2011). As already mentioned, core histones have a predominantly globular 
structure with flexible C- and N-terminal tails, which are unstructured and protrude from the 
nucleosomes core body. The histones and particularly the N-terminal tails of H3 and H4 are 
subject to a large number and type of modifications; especially modifications of the N-
terminal tails are well characterized (Figure 2) (Zhao & Garcia 2015). Altogether, at least 8 
chemically different modifications are occurring at more than 60 different sites and the list is 
still growing (Rousseaux & Khochbin 2015; Xu et al. 2014). Extensively studied 
modifications are phosphorylation (S and T), acetylation (K) and methylation (K and R). 
Apart from that, also ubiquitination (K), symoylation (K), ADP ribosylation, glycosylation, 
biotinylation and carbonylation are established PTMs (Margueron et al. 2005). Histone 
modifications can directly influence the chromatin structure by changing the charge of the 
amino acid. For example, acetylation neutralizes the positive charge of a lysine residue and 
thereby weakens the electrostatic interaction between nucleosomes and the surrounding DNA. 
Hence, the chromatin structure is converted to a less compact state which facilitates the 
accessibility of chromatin and leads to transcriptional activation. Indirectly, these 
modifications can recruit effector protein complexes with specific binding properties, also 
called “reading domains” (Bannister & Kouzarides 2011; Kouzarides 2007; Fischle, Wang & 
Allis 2003). They are categorized in groups, depending on the detection of distinct histone 
modifications. Effector proteins containing a bromodomain recognize acetylation, while 
phosphorylation is known to be bound by 14-3-3 proteins. Methylation can be identified by 
chromo-like domains of the Royal family (chromo, tudor, PWWP and MBT), ankyrin repeats 
and PHD domains (Kouzarides 2007). The heterochromatin protein (HP1) is one example for 
an effector protein that recognizes the H3K9me3 mark with its chromodomain and majorly 
facilitates the heterochromatin formation and gene repression (Daniel et al. 2005).  
5Histone posttranslational modifications are very dynamic compared to DNA methylation and 
specific sites of the genome can undergo various modifications. Lysine residues, for example, 
are subject to methylation (mono-, di-, and tri-), acetylation, acylation, ubiquitination and 
sumoylation, but these different modifications cannot co-exist at the same time at the same 
residue. In agreement with this presumption, researchers identified complexes, which contain 
histone deacetylases together with histone methyltransferases. In this case an acetyl group is 
removed from a lysine, before a methyl group can be introduced (Vaute et al. 2002). 
Generally, lysine acetylation is always associated with activated genomic regions, whereas 
lysine methylation can be correlated with transcriptional activation and repression, depending 
on the genomic site and level of methylation (Bannister & Kouzarides 2011; Fischle, Wang, 
Jacobs, et al. 2003). Histone modifications can influence each other, when they are located on 
the same histone tail, a process called “cis effect”. Interestingly, also communication exists 
between adjacent nucleosomes, characterized as “trans effect”. For example, it was shown 
that ubiquitination of H2B is necessary for the methylation of H3K4 and H3K79 (Fischle, 
Wang & Allis 2003; Kouzarides 2007). Altogether, the sum of all possible PTM combinations 
at different sites is described as the “histone code”, which may encode specific functional 
states (Jenuwein & Allis 2001). 
Figure 2: Schematic overview of posttranslational histone modifications. The main posttranslational modifications of the 
unstructured N-terminal tail and globular domain (boxed) of H3, H4, H2A and H2B are represented. Phosphorylation (P) is 
shown as light green circle, acetylation (Ac) as turquoise flag, arginine methylation (Me) as violette hexagon, active lysine 
methylation (Me) as green and yellow hexagon, repressive lysine methylation (Me) as red hexagon and ubiquitination (Ub) as 
blue ellipse. The figure is taken from the book “Epigenetics Second Edition”. New York: Cold Spring Harbor Laboratory 
Press; Chapter 3, page 57; 2015. 
1.6. Histone methylation 
Histone methylation on lysine and arginine residues is one of the most studied 
posttranslational modification. It is found on all four histone proteins, but majorly on the H3 
6and H4 N-terminal tail. Lysine residues can be mono-, di- and trimethylated at the ε-amino 
group and arginine residues can be mono- or dimethylated at the ω-guanidino group, either 
symmetrically or asymmetrically (Bannister & Kouzarides 2011; Margueron et al. 2005). 
Lysine methylation is introduced by protein lysine methyltransferases (PKMT) and is 
removed by protein lysine demethylases (PKDM). Arginine methylation is set by protein 
arginine methyltransferases (PRMTs), but no specific enzyme has been identified to reverse 
arginine methylation (Allis et al. 2007). However, an indirect effect is known, where the 
protein arginine deiminase converts methylarginine to citrulline (Bannister & Kouzarides 
2005; Kouzarides 2007). The subject of interest of this thesis mainly was lysine methylation, 
which was first described in 1964 by Murray (Murray 1964). Different from histone 
acetylation, methylation does not change the electrostatic interaction between DNA and 
histones. Instead, effector protein complexes are recruited to the specifically methylated 
lysine residues that subsequently alter the chromatin properties (Bannister & Kouzarides 
2005; Kouzarides 2007; Gelato & Fischle 2008; Martin & Zhang 2005). As the biological 
outcome of histone methylation is dependent on the methylated site and level of methylation, 
its understanding is very complex. Five major lysine methylation sites on histones have been 
extensively studied, viz. H3K4, H3K9, H3K27, H3K36, H3K79 and H4K20 (Kouzarides 
2007). Out of these, H3K4, H3K36 and H3K79 methylation are associated with 
transcriptional activity, while methylation of H3K9, H3K27 and H4K20 is found on repressed 
chromatin (Kouzarides 2007). 
1.7. Protein lysine demethylases 
For a long time, methylation of the ε-amino group of lysine was considered to be irreversible 
due to the formation of a strong C-N bond. Still, it was known that the methylation level 
changes during biological processes, for instance cellular differentiation and the existence of 
enzymes catalyzing the removal of methyl groups was expected (Bannister et al. 2002). 
Finally, in 2004 Shi et al. identified the first lysine specific demethylase 1 (LSD1, KDM1A), 
which catalyzes the process of H3K4 Nε-demethylation (Shi et al. 2004). KDM1A catalyzes 
an amine oxidation reaction, using a flavin adenine dinucleotide as cosubstrate. After the 
transfer of a hydride from the Nε-methyl group onto FAD, an imine is produced, which is 
unstable to hydrolysis and the methyl group is released as formaldehyde. LSD1 and its 
paralog LSD2 are reported to demethylate H3K4me1/me2 and H3K9me1/me2. However, 
demethylation of trimethylated lysine targets is precluded, because the amine oxidation 
reaction requires protonated nitrogen as substrate. Two years later, Tsukada et al. discovered 
7another histone demethylase, JHDM1 (JmjC domain-containing histone demethylase 1) that 
demethylates H3-methyl K36 (Tsukada et al. 2006). Over time many more Jumonji type 
histone demethylases were discovered and by now they are categorized in six main families 
called lysine demethylases (KDM2-7), dependent on their amino acid sequence (Thinnes et al. 
2014). The Jumonji-containing lysine demethylases catalyze an Fe(II) dependent dioxygenase 
reaction using α-ketoglutarate and dioxygen as cosubstrates, generating formaldehyde and 
succinate. In contrast to the KDM1 subfamily, which is only able to catalyze demethylation of 
mono- and dimethylated lysine residues, KDM2-7 enzymes can catalyze the removal of all 
three methylation forms at multiple sites. Overall both subfamilies have overlapping functions 
and dysregulation seems to be linked to diseases, including cancer and genetic disorders (Shi 
et al. 2004; Thinnes et al. 2014; Tsukada et al. 2006; Upadhyay & Cheng 2011). 
1.8. Protein lysine methyltransferases 
The discovery of the first histone lysine methyltransferase Suv39h1 in 2000 by Jenuwein and 
colleagues was a milestone for understanding lysine methylation is the epigenetic control 
(Rea et al. 2000). During the last more than 15 years, the research on posttranslational 
modifications and enzymes, regulating these epigenetic mechanisms, made an impressive 
progress. By now approximately 80 PKMT enzymes have been identified (Zhang et al. 2012; 
Jenuwein 2006). Having more detailed information about each enzyme available, it became 
clear that the network of all known PKMTs is more complex than expected before. Different 
PKMTs can methylate the same target site, whereas also one single PKMT can catalyze the 
methylation of different target sites. Moreover, the methylation levels, catalyzed by specific 
protein lysine methyltransferases, can be influenced by the recruitment of interaction partners. 
Initially, only histones were considered as substrates for histone lysine methyltransferases, but 
subsequently also non-histone targets (NHT) were identified as target substrates for some 
PKMTs (G9a, SET7/9) (in more detail 1.9). The investigation of novel non-histone targets of 
different PKMTs is still in progress, which means this field will experience further progress in 
future (Zhang et al. 2012). 
To keep an overview, enzymes catalyzing the lysine and arginine methylation of proteins are 
divided in three distinct protein families: the protein arginine methyltransferases (PRMT), the 
non-SET domain containing protein lysine methyltransferases like Dot1/DOT1L and the SET 
domain containing protein lysine methyltransferases (PKMT) (Feng et al. 2002; Dillon et al. 
2005). Regarding their substrate specificity and sequence homology, PKMTs are divided in 8 
families called lysine methyltransferases (KMT) 1-8 (Allis et al. 2007). 
81.8.1. The overall SET domain structure 
Most PKMTs contain a SET domain, which is a conserved 130 amino acids long structure 
found in enzymes from Saccharomyces cerevisiae to human (Dillon et al. 2005; Rea et al. 
2000). The name SET arise from the first three identified proteins in Drosophila 
melanogaster containing this domain: Suppressor of variegation 3-9 (Su(var)3-9), a modifier 
of position-effect variegation; Enhancer of zeste (E(z)), a chromatin regulator of the 
Polycomb group and Trithorax (Trx), the chromatin regulator of the Trithorax group (Dillon 
et al. 2005; Rea et al. 2000). The structural fold of the SET domain is unique compared to 
other methyltransferases using AdoMet as methyl-group donor, like DNA methyltransferases 
or protein arginine methyltransferases. The core SET domain consists of several β-sheets, 
which are organized into three distinct sheets, surrounding a so-called “pseudo-knot” 
structure. This knot-like structure is formed by the C-terminal tail of the SET domain 
threading through a loop, which is formed by a sequence protruding from the structure. 
Moreover, the pseudoknot contains the two most conserved sequence motifs ELxF/YDY and 
NHS/CxxPN and thereby it is very important to bring the cofactor binding site and the peptide 
binding cleft in close proximity to the active pocket (Figure 3) (Qian & Zhou 2006).  
At the N- and C-termini, the core SET domain is flanked by the pre- and post-SET domains, 
respectively, which are not conserved within the protein lysine methyltransferases. While the 
pre-SET domain works as a stabilizing element by interacting with domains of the core SET 
domain, the postSET domain completes the active site and forms the characteristic 
hydrophobic channel, which will be explained later in detail (Qian & Zhou 2006; Dillon et al. 
2005; Xiao et al. 2003). Some PKMTs additionally contain an inserted region (iSET), which 
varies in length and is not conserved. In the three dimensional structures of SET domains 
bound to cofactor and substrate, it was shown that the iSET region directly binds the peptide 
substrate and thus contributes to the substrate specificity. For example, MLL1 and SET7/9 are 
both H3K4 methyltransferases, but contain enzyme specific iSET regions and thereby 
recognize different residues in the same target substrate (Xiao et al. 2003; Qian & Zhou 
2006). 
1.8.2. The catalytic active pocket 
Compared to other AdoMet dependent methyltransferases, SET domain containing lysine 
methyltransferases have a unique rearrangement of the substrate peptide binding pocket and 
AdoMet binding site, which are located at opposite sides of the SET domain connected 
through a narrow hydrophobic channel. When the cofactor is bound, AdoMet is positioned in 
9a U-shaped conformation due to the hydrogen bond formation to residues in the conserved 
NHS/CxxPN motif of the pseudo-knot structure and the GxG motif in the preSET domain. In 
addition, the carboxylate of AdoMet forms a salt bridge with a conserved arginine or lysine in 
the SET domain. This conformation is necessary to place the AdoMet methyl group at the 
base of a hydrophobic channel. On the other side of this channel, the lysine residue of the 
substrate is inserted, such that the channel links the substrate peptide with the cofactor 
AdoMet. Within the hydrophobic channel, a conserved tyrosine residue deprotonates the ε-
amino group of the lysine site chain and allows for a nucleophilic attack of lysine on the 
AdoMet methyl-group. 
Figure 3: SET domain structures of (a) Neurospora crassa DIM-5 and (b) human SET7/9. The structures show the PostSET, 
SET and Pre-SET domain in grey, green and yellow, respectively. Also indicated is the characteristic pseudo-knot structure 
in pink. The substrate peptide H3 is visualized in red and the cofactor product AdoHcy as a stick model in blue. The figure is 
taken from (Dillon et al. 2005). 
1.8.3. The Phe/Tyr switch controlling the product specificity of PKMTs 
As already mentioned, the postSET domain contributes to the formation of the active site 
cavity of SET domain PKMTs. Mutational analyses have shown that the nature of one 
particular residue in the postSET region determines the methylation level of specific enzymes. 
Enzymes containing a tyrosine residue at this position, like Tyr245 of SET7/9, are 
monomethyltransferases, whereas enzymes containing a phenylalanine residue at this 
position, like Phe281 of Dim-5, catalyze trimethylation. This effect can be explained by the 
reaction mechanism of the enzymes. During the reaction of methyl transfer the tyrosine 
(Tyr245 of SET7/9) interacts via hydrogen bonds with the ε-amine of lysine and by this 
orients the lone pair of the lysine towards the methyl group of AdoMet. After deprotonation 
of the ε-amine of the lysine, an SN2 nucleophilic attack of the lysine on the methyl group of 
AdoMet occurs and monomethyllysine together with AdoHcy are produced. As the hydrogen 
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bond is still present, the rotation of the lysine ε-carbon-nitrogen bond is hindered. Conversely, 
phenylalanine at this position (Phe281 in Dim-5) allows the lysine ε-carbon-nitrogen bond to 
rotate, so that the ε-amine can be further deprotonated without release of methyllysine in a 
processive methylation mechanism (Copeland et al. 2009; Smith & Denu 2009). Mutation of 
Phe281 to tyrosine has been shown to reduce the methylation level of Dim5 from 
trimethylation to mono- and dimethylation. In this aspect, the F/Y switch position is an 
important site to discriminate how many methyl groups can be transferred from the methyl 
donor cofactor AdoMet to the ε-amino lysine residue, dependent on the geometry and size of 
the lysine channel (Dillon et al. 2005; Qian & Zhou 2006; Upadhyay & Cheng 2011; Xiao et 
al. 2003; Collins et al. 2005). 
1.8.4. Readout of lysine methylation marks 
As described so far, posttranslational modifications of histones are important for epigenetic 
control mechanisms. However, the question remains how these different chemical 
modifications can be translated into specific biological outputs. Two models of “direct” and 
“effector mediated” readout are established for the translation of the epigenetic code. By 
charge removal induced chromatin decondensation, histone acetylation can directly stimulate 
expression. As an alternative modified residues can recruit reading domains for the translation 
of the modification into a biological output (Bannister & Kouzarides 2005; Kouzarides 2007; 
Gelato & Fischle 2008; Martin & Zhang 2005). 
In case of histone lysine methylation, reading domains provide a specific surface to recognize 
the posttranslational modification and to discriminate different methylation states. Major 
families of domains involved in the readout of methyl lysine marks are the Royal superfamily 
(chromodomain, tudor, PWWP and MBT), ankyrin and PHD domains (Patel & Wang 2013; 
Taverna et al. 2007). Methyllysine (MeK) binders typically have a binding pocket consisting 
of 2-4 aromatic residues and additionally acidic residues, forming an aromatic cage (Taverna 
et al. 2007). Considering the amount of aromatic residues, MeK binding pockets can be 
classified as “half” aromatic cage or “full” aromatic cage. To discriminate between the 
methylation levels of target sites, binding pockets with different recognition modes exist. The 
cavity insertion mode binds mono- and dimethylated lysine residues through hydrogen bonds 
and electrostatic interactions between the methylammonium proton and the carboxylate group 
of acidic residues (aspartate), whereas higher methylation forms are structurally excluded 
(tandem tudor domain of 53BP1 and L3MBTL1). Trimethylated lysine residues are 
recognized by reading domains with a “surface groove” pocket, which is lined by three 
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conserved aromatic amino acids. It can stabilize the trimethylated lysine by cation-pi
interactions (Taverna et al. 2007; Yun et al. 2011). Hence domains binding lower methylation 
states tend to have a half pocket, while Kme3 specific domain contain a full pocket. However, 
this classification does not always correspond to the methylation level of specific genome 
sites. Unmethylated lysine residues are bound by intermolecular hydrogen bonds, but 
corresponding readers do not have a characteristic binding pocket (BHC80 PHD domain) 
(Yun et al. 2011).  
All members of the Royal family fold in an incomplete β-barrel structure consisting of four 
antiparallel β-strands and the binding of the histone peptide, also folded as β-strand, complete 
the β-barrel structure. Well characterized is the β-barrel conformation of the heterochromatin 
protein 1 (HP1) bound to H3K9me3, which contributes to gene silencing. The solved crystal 
structure of this complex showed that reading domains are also dependent on flanking 
sequences of the Kme3 residue to distinguish sequence contexts, because HP1 also binds 
three amino acids preceding and one amino acid following the H3K9me3 mark (Figure 4) 
(Taverna et al. 2007; Yun et al. 2011; Patel & Wang 2013). This indicates that readout of 
posttranslational modifications is sequence specific and the recruitment of additional proteins 
allows the system to work in concert with other epigenetic systems. 
Figure 4: HP1 is a reading domain from the Royal superfamily. a) Crystal structure of HP1 bound to trimethylated H3(1-
15)K9 peptide. It also recognizes flanking sequences of H3K9 from Q5 to S10. B) The peptide H3K9me3 folds as a β-strand 
and binds between two β-strands of HP1, resulting in the formation of a complete three stranded antiparallel β-barrel 
structure. The figure is taken from (Patel & Wang 2013).
1.9. Non-histone targets 
High throughput proteomic studies led to the identification of many lysine methylation events 
at non-histone proteins, which are involved in the regulation of important biological 
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processes, like protein activity and stability, as well as interactions between different proteins 
(Zhang et al. 2015; Clarke 2013; Huang & Berger 2008; Lanouette et al. 2014). However, for 
many lysine methylation sites, the corresponding PKMT is not known or on the other hand, 
for many PKMTs, the complete variety of all possible cellular substrates is not yet identified 
(Figure 5A/B) (Kudithipudi & Jeltsch 2016). The first example of an histone lysine 
methyltransferase that can methylate a non-histone target was SET7/9, shown to methylate 
the tumor suppressor protein p53 (Chuikov et al. 2004). Beside SET7/9, also SMYD2, SET8 
and G9a were recognized to methylate p53 at distinct lysine residues with different biological 
outcome. While SET7/9 methylation of p53 at lysine 372 results in activation of p53 
regulated gene expression, methylation by SMYD2 (K370) and SET8 (K372) cause 
inactivation of p53 (Huang et al. 2006; Shi et al. 2007; Kurash et al. 2008). Afterwards 
additional PKMTs, like SMYD3, G9a, NSD1/2, SUV39H1/H2 etc. (Figure 5C) were shown 
to methylate non-histone substrates as well (Kudithipudi & Jeltsch 2016; Zhang et al. 2015). 
In addition, not only PKMTs can modify NHT, also the demethyltransferase LSD1 regulate 
the methylation level of p53 (Huang et al. 2007).  
Figure 5: Identification of novel targets for protein lysine methyltransferase. A) For most PKMTs, the list of possible targets 
is not identified yet. B) For most methylated target sites, the responsible PKMT is unknown. C) List of PKMTs, including 
their systematic names, alternate names, histone substrates and identified non-histone substrates. Figures are taken from 
(Kudithipudi & Jeltsch 2016).  
With increasing interest in PKMTs, due to the discovery of non-histone proteins as possible 
targets, many methylation sites in the proteome of human cells were identified in a very short 
time, but also wrong assignment of PKMTs and methylation sites occurred. For example, 
NSD1 initially was characterized as H3K36 and H4K20 methyltransferase, however later 
sequence specificity analysis have shown that H4K20 does not fit to the specificity profile, 
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but rather H4K44 is methylated by NSD1 (Kudithipudi, Lungu, et al. 2014; Rayasam et al. 
2003). Also SMYD2, initially reported as a H3K36 dimethyltransferase was shown to 
methylate p53 and retinoblastoma protein (RB) in addition to more NHT, whereas 
methylation of histone proteins could not be detected in later studies (Huang et al. 2006; 
Brown et al. 2006; Saddic et al. 2010). As dysregulation of protein lysine methyltransferases 
is often related to the development of diseases, wrong assignments of PKMT substrates can 
provoke big confusion, lead to wrong interpretation of biological processes and in the worst 
case to the development of misleading therapeutic strategies. To improve the reliability of the 
assignment of PKMTs with specific substrates and lysine methylation events, a guideline with 
seven rules was proposed recently (Kudithipudi & Jeltsch 2016). This guideline requires that 
methylation events of novel targets have to be further investigated. It is necessary to check if 
the methylation of the novel target is relevant by including positive controls. Furthermore, it 
has to be verified if the predicted target lysine is methylated and also if the protein lysine 
methyltransferase is really the methylating enzyme. The sequence of the putative non-histone 
target has to fit to the sequence preference of the enzyme. Beside quality analysis, also 
quantitative measurements have to be done to assess potential biological relevance of a 
methylation event. 
Today, different approaches exist for the identification of novel PKMT substrates. Beside 
protein interaction analysis and biochemical purification, substrate specificity analysis of 
PKMTs is often used for a proteome wide screening of NHT of specific PKMTs. Independent 
which method was used, the critical part is always the validation of the methylation event in 
vitro and in vivo. Only with this confirmation relevant biological functions can be 
systematically connected to an identified methylation event and further improve the 
development of therapeutic drugs (Kudithipudi & Jeltsch 2016; Rathert, Dhayalan, Ma, et al. 
2008). One main topic of this thesis was the investigation of novel non-histone targets of 
different histone methyltransferases, and it was also demonstrated that some assignments of 
PKMT substrates in the literature are incorrect. 
1.10. Somatic cancer mutations in PKMTs 
Over the past decades, sequence technologies have been massively improved and current next 
generating sequencing (NGS) allow analyses of whole exomes or even genomes at reasonable 
costs. In genome wide sequencing studies of cancer tissues, several somatic cancer mutations 
in PKMTs were discovered and proposed to have a central role in carcinogenesis (Watson et 
al. 2013). The “Catalogue Of Somatic Mutations In Cancer” (COSMIC) database has listed 
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all known somatic cancer mutations in various tumors and also provides information about 
the localization of mutations in the genome and in different cancers (Forbes et al. 2011). In 
general, somatic cancer mutations in epigenetic factors can be categorized in two functional 
groups, loss-of-function and gain-of-function mutations. Chromosomal translocations, which 
lead to alterations in the expression level of specific genes or recruit enzymes to aberrant 
genomic loci, represent a well-known mechanism for gain-of-function mutations. Non-sense 
or frameshift mutations in the coding region of genes induce loss of the protein function 
(Kudithipudi & Jeltsch 2014). However, some somatic cancer mutations cannot be strictly 
assigned in one of these two groups. Missense mutations are point mutations of single amino 
acids and can have various effects, dependent on the site of the mutation and the resulting 
amino acid substitution. In Figure 6A, possible effects of missense mutations in PKMTs are 
summarized. The disruption of AdoMet binding is one possible mechanism to inactivate an 
enzyme, as well as the disruption of the protein fold. Otherwise, point mutations can influence 
the interaction with other proteins, which may affect the regulation and targeting of PKMTs. 
Additionally, missense mutations can change the peptide recognition motif, due to that new 
substrates can be recognized, but probably the original substrate cannot be methylated 
anymore. Finally, the methylation level of the product can be altered (Kudithipudi & Jeltsch 
2014). In B-cell lymphoma cell lines and follicular lymphoma samples, somatic cancer 
mutations of EZH2, the catalytically active component of the polycomb repressive complex 2 
(PRC2), were found, which provide a well understood example of the latter mechanism. 
Wildtype EZH2 catalyzes mono- and dimethylation of H3K27 using unmethylated substrate 
as target. Mutation of Y641 changes the methylation level to H3K27me3 and also alters the 
substrate preference. Tyrosine 641 is located in the aromatic cage of the SET domain and 
formation of a hydrogen bond with the ε-amino group of lysine prevents trimethylation of 
H3K27. An amino acid exchange of Y641 leads to increased H3K27me3 levels and silencing 
of tumor suppressor genes (Morin et al. 2010; Sneeringer et al. 2010; Yap et al. 2011). 
Dependent on previous roles of a PKMT in regulating oncogenes or tumor suppressor genes, 
loss-of-function or gain-of-function mutations of PKMTs can reverse their function and play a 
fundamental role in tumor growth (Figure 6B) (Kudithipudi & Jeltsch 2014).  
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Figure 6: Somatic cancer mutations in PKMTs can have different biological effects. A) Summary of possible effects of 
missense mutations. B) Loss-of-function or gain-of-function mutations of PKMTs can reverse original functions of 
oncogenes or tumor suppressor genes. Figures are taken from (Kudithipudi & Jeltsch 2014).
For the understanding of the role of somatic cancer mutations in PKMTs, it is necessary to 
study the in vitro and in vivo effects of each mutation in detail. While loss-of-function 
mutations often can be easily explained on the background of the gene function, the 
understanding of the effect of gain-of-function mutations is more complex, because each 
mutation can have independent biochemical functions as described above. Hence, each mutant 
may also need specific therapeutic treatment. During carcinogenesis, aberrant histone 
methylation can be prevented, using PKMT inhibitors as a common cancer treatment strategy, 
but this approach cannot be used for the treatment of inactive PKMT mutants. Therefore, 
future biomedical research needs individual biochemical and cellular investigation of each 
somatic cancer mutation of PKMTs to know the consequence of somatic mutations in PKMTs 
and to focus on the establishment of individual cancer treatment. 
1.11. Histone H4 lysine 20 methylation 
Methylation of lysine 20 of histone H4 is correlated with transcriptional repression. H4K20 
can be mono-, di- and trimethylated. Each methylation state has distinct biological roles; 
trimethylation of H4K20 leads to heterochromatin formation and gene silencing, 
monomethylation plays a role in cell cycle progression, genomic stability, DNA replication 
and DNA damage response (Jørgensen et al. 2013; Beck et al. 2012). In Schizosaccharomyces 
pombe one single methyltransferase is responsible for setting all three methylation states of 
H4K20. In human cells several enzymes have been reported to introduce the different 
methylation states of H4K20. The three most important PKMTs are SET8, catalyzing H4K20 
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monomethylation, SUV4-20H1 and SUV4-20H2 catalyzing H4K20 di- and trimethylation 
(Beck et al. 2012; Balakrishnan & Milavetz 2010). Lack of SET8 caused a complete loss of 
H4K20 methylation, including H4K20 di- and trimethylation indicating that SUV4-20H1/H2 
use H4K20me1 as preferred substrate for methylation. Studies with double knock-out of 
SUV4-20H1 and H2 have shown a decrease in H4K20me2/me3 together with an increasing 
amount of H4K20me1, which suggests that SET8 can only introduce one single methyl group 
and it is not able to catalyze further methylation states (Schotta et al. 2008). In vitro
methyltransferase activity analyses of SUV4-20H1 and SUV4-20H2 have shown that both 
enzymes transfer one methyl group to monomethylated H4K20 peptide substrates (Southall et 
al. 2014; Wu et al. 2013), but results differed in details. Wu et al. (2013) observed a ~3 fold 
preference for monomethylated H4K20 substrate, whereas Southall et al. (2014) reported that 
SUV4-20H enzymes prefer H4K20me1 by about 10 fold. In both studies dimethylation of 
monomethylated target substrate was detected as well, but no trimethylation was observed. In 
contrast, H4K20 trimethylation was shown with nucleosomes as substrate (Schotta et al. 
2004). Knock-out studies of SUV4-20H1 and SUV4-20H2 in mice and zebrafish have shown 
massive loss of H4K20me2 and me3 indicating that the SUV4-20H enzymes are responsible 
for introducing both in vivo (Kuo et al. 2012; Schotta et al. 2008; Southall et al. 2014). 
Schotta et al. (2004) suggest a model where H4K20 trimethylation at pericentric 
heterochromatin is dependent on H3K9 trimethylation by Suv3-9 methyltransferase due to 
interaction with HP1 isoforms (Schotta et al. 2004; Southall et al. 2014). 
Expression studies have shown that SUV4-20H1 is ubiquitously expressed during 
embryogenesis and is also found in all adult tissues, whereas SUV4-20H2 is only detectable 
in some adult tissues and expression during development is low. Knock-out experiments have 
shown that SUV4-20H1-/- mice have developmental defects and die due to perinatal lethality. 
In comparison to that, SUV4-20H2-/- mice have no apparent problems during development, 
although they have decreased H4K20me3 levels at pericentric chromatin (Schotta et al. 2008). 
These results show that the two paralogs of H4K20 methyltransferases, present in mammalian 
cells, have non-redundant functions (Schotta et al. 2008). 
The expression level of SET8 is fluctuating during cell cycle progression. In the G1 phase the 
expression level of SET8 is decreased reaching a very low level at the beginning of the S 
phase. During S and G2 phase the SET8 level increases until a peak is reached in the M 
phase. In the same way, the H4K20 monomethylation mark oscillates during cell cycle 
progression, as cells entering the S phase start to incorporate new histone proteins without 
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H4K20 methylation. With increasing SET8 levels until G2, H4K20me1 is introduced, which 
remains stable during mitosis and is converted to H4K20me2/me3 in the G1 phase of the cell 
cycle (Beck et al. 2012). Loss of SET8 leads to embryonic lethality in mice, due to increased 
DNA damage and dysregulated cell cycle progression (Oda et al. 2009).  
1.11.1. Catalytical activity and specificity of SET8 
Similar to other histone lysine methyltransferases, SET8 also contains a catalytic SET domain 
and by resolving the crystal structure of SET8 in complex with AdoHcy and peptide substrate 
the monomethyltransferase activity could be explained. It was shown that two tyrosine 
residues (Tyr245 and Tyr334) located in the binding pocket of SET8 form direct or water-
mediated hydrogen bond interactions with ε-amino group of lysine 20, respectively. Hydrogen 
bonds between the hydroxyl group of Tyr334, the carbonyl groups of Gly294 and Ile297 and 
the ε-amine group of K20me1 tightly interact with a water molecule. This strong binding of 
the water molecule hinders the K20me1 group from rotation in the cofactor binding site 
preventing further methylation reactions (Del Rizzo & Trievel 2014; Couture et al. 2005). 
Mutational analysis revealed that exchange of tyrosine at position 334 to phenylalanine 
enables SET8 to dimethylate H4K20 (Couture et al. 2005). 
In agreement with the crystal structure of SET8, a substrate specificity analysis has indicated 
that SET8 has a long recognition motif ranging from R17 to R23 (R17-H18-(R19KY)-K20-
(V21ILFY)-(L22FY)-R23) and amino acid exchanges at R17 and H18 caused a complete loss of 
methyltransferase activity. Similar as other histone lysine methyltransferases, SET8 also 
methylate non-histone proteins. The methylation of p53 at K382 was discovered as the very 
first non-histone target of SET8. Methylated p53 is bound by L3MBTL1 (Lethal 3 malignant 
brain tumor 1) via its MBT domains, repress the expression of p53 target genes and finally 
leads to chromatin compaction (West et al. 2010). Furthermore, it was reported that SET8 
dimethylates the Numb protein at K158 and K163. Numb was identified in Drosophila as a 
cell-fate determinant during development that interacts with p53 in the nucleus. Methylation 
of Numb was reported to disrupt its interaction with p53, which was described to result in 
increased p53 ubiquitination and reduced apoptosis (Dhami et al. 2013). Sequence 
comparisons of the residues flanking the reported target lysine residues of Numb indicated 
that these methylation sites differ from the SET8 requirements. In addition, SET8 was 
reported to act as a strict monomethyltransferase and dimethylation of lysine residues by 
SET8 was not identified before, which stands in contrast to the reported dimethylation activity 
of SET8 on Numb. Therefore, in this thesis I further investigated Numb methylation by SET8.  
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1.11.2. Catalytical activity and specificity of SUV4-20H1 and SUV4-20H2 
The catalytic domains of SUV4-20H1 and H2 contain an N-terminal helical domain, the SET 
domain and Zn-binding postSET domain. Even if the overall fold of the catalytic SET domain 
is similar to other PKMTs, a sequence comparison of the SET domain indicates only 8-22% 
identity to other SET enzymes. However, the catalytic domain of SUV4-20H1/H2 harbor a 
sequence identity of 65%. The discovery of a unique mechanism of SUV4-20H enzymes, to 
catalyze dimethylation using monomethylated substrate as target, was quite interesting. As 
described above, methyltransferases known to catalyze monomethylation of lysines residues 
contain one tyrosine residue in the canonical SET domain that interacts with the ε-amino 
group of the target lysine. In case of SUV4-20H proteins, a serine residue (S251 for SUV4-
20H1 and S161 for SUV4-20H2) forms a hydrogen bond between its hydroxyl side chain and 
the target lysine Nε (instead of Y245 in SET8). Another tyrosine (Y334 in SET8) is replaced 
by a cysteine in both enzymes (Cys305 in SUV4-20H1 and Cys215 in SUV4-20H2). The 
transfer of only one methyl group can be explained by the hydrogen bond formed by 
Ser251/161 and the ε-amino group of the target lysine which may hinder the transfer of a 
second methyl group, because it can prevent rotation of the amino group. Additionally, the 
methyl group of H4K20me1 is bound in a well-defined hydrophobic pocket formed by 
Ile204/Ile181 and Phe214/Phe191 in SUV4-20H1/H2, where unmethylated H4K20 cannot 
bind, which explains the preference for a monomethylated substrate (Figure 7).SET8 and 
SUV4-20H enzymes have differences in their enzymatic properties and substrate binding. 
Comparison of the substrate binding site and the active pocket of SET8 and SUV4-20H 
enzymes imply that even if they recognize the same substrate target H4K20, different 
interaction between the adjacent amino acids are present (Wu et al. 2013; Southall et al. 
2014). This suggests that there might be also differences regarding the sequence specificity 
between SUV4-20H1 and SUV4-20H2, which has to be further investigated. It also indicates 
that both paralogs might recognize different non-histone targets which leads to new insights 
into unclear biological processes. Further analyses are necessary to discriminate the substrate 
specificity of SUV4-20H1 and H2, and to search for new non-histone targets, which has been 
part of this thesis. 
Recently, the extracellular signal-regulated kinase 1 (ERK1) was reported to be trimethylated 
by SUV4-20H1 at two different lysine residues: K302 and K361. This methylation was 
connected to increased phosphorylation and transcription, followed by enhanced ERK1 
signaling cascade finally resulting in tumorigenesis (Vougiouklakis et al. 2015). However, 
trimethylation activity of SUV4-20H1 using an unmethylated lysine as substrate is in 
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disagreement with the published data about the substrate specificity and product pattern of 
SUV4-20H1 described above (Southall et al. 2014). Also the sequences surrounding the 
predicted target lysines are not matching with the substrate specificity of both enzymes 
determined in this thesis. Therefore, a further analysis of ERK1 methylation by SUV4-20H 
enzymes was conducted as part of this thesis. 
Figure 7: A) In conventional monomethylases (SET8) two tyrosine residues in the binding pocket form direct or water-
mediated hydrogen bonds with the ε-amino group of lysine 20, respectively. B) In contrast to SET8, SUV4-20H enzymes 
have a serine residue that forms a hydrogen bond between its hydroxyl side chain and the target lysine Nε. C) A well-defined 
hydrophobic pocket formed by isoleucine and phenylalanine residues of SUV4-20H enzymes prefer monomethylated H4K20 
so unmethylated H4K20. Figures are taken from (Southall et al. 2014).  
1.12. The MLL histone lysine methyltransferase family  
The mixed-lineage leukemia (MLL) family of histone lysine methyltransferases regulates the 
expression of homeotic and developmental genes (Smith et al. 2011; Ansari et al. 2009). In 
yeast, Set1 is the single histone lysine methyltransferase catalyzing all mono-, di- and 
trimethylation of lysine 4 on histone H3. In Drosophila melanogaster, three H3K4 
methyltransferases: SET domain-containing 1 (Set1), Trithorax (Trx) and Trithorax-related 
(Trr) are present. In human cells each of the three H3K4 Drosophila melanogaster
methyltransferases is represented by two homologs, so that the mammalian MLL protein 
family consists of six members in total: MLL1/MLL2 (related to Trx), MLL3/MLL4 (related 
to Trr) and SET1A/SET1B (related to Set1) (Piunti & Shilatifard 2016). Additionally MLL5 
exists, but so far no enzymatic function could be discovered (Mas-y-Mas et al. 2016). 
Each MLL protein has a specific domain organization. As shown in Figure 8A, all MLL 
proteins contain the catalytic SET domain, followed by a postSET domain at the C-terminus. 
MLL1-4 have several additional domains, like plant homeodomains (PHD) or bromodomains 
(Bromo), which facilitate modified histone interaction. Additionally, all four MLL proteins 
contain an FYRN-FYRC (Phe/Tyr residues N-terminal - Phe/Tyr residues C-terminal) 
domain. Crystal structures of MLL1-4 indicate that these parts fold as one single domain and 
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stay together in cells (Smith et al. 2011). During maturation, MLL1 and MLL2 are cleaved 
into a C- and N-terminal fragment by the protease Taspase 1. The Taspase cleavage site is 
located in a gap of 1595 amino acids in MLL1 and 631 amino acids in MLL2 between the 
FYRN and FYRC domains. In contrast, in MLL3 and MLL4, the FYRN and FYRC domains 
are located next to each other. At the N-terminal end, MLL1 and MLL2 carry a CxxC domain 
that has been shown to bind to unmethylated CpG DNA sites. Moreover AT-hooks are 
present in MLL1/2, which are involved in the localization to specific target gene loci (Macrini 
et al. 2003; Cierpicki et al. 2010). In contrast to the other enzymes of this family, the SET 
proteins (Set1, SET1A and SET1B) have only one or two RNA recognition motifs (RRM) 
located at the N-terminus. 
Cellular studies indicated that the MLL proteins have non redundant functions, as mice 
containing MLL-deletion and -truncation constructs showing different phenotypes (Ansari et 
al. 2009), because they introduce different methylation states on H3K4 at distinct genomic 
regions. MLL1 and MLL2 catalyze trimethylation of H3K4 sites located at gene promotors, 
especially of Hox genes, whereas SET1A and SET1B proteins introduce genome-wide H3K4 
trimethylation in mammals. MLL3 and MLL4 mainly introduce monomethylation marks on 
H3K4 sites at enhancers and promotors of target genes (Cheng et al. 2014). 
Within all MLL family members, MLL1 is the most studied one, because it is involved in 
chromosomal translocations often found in patients with acute myeloid and lymphoid 
leukemia. In about 75% of MLL1 associated leukemia, the N-terminal part of MLL1 is 
genetically fused with 60 different partner genes, mostly AF4, AF9, AF10 and ENL. One part 
of the fusion protein is the DNA binding domain of MLL1, which delegates them to MLL1 
specific target genes. The catalytic domain of MLL1 is exchanged by the fusion partners 
leading to an altered target gene regulation at the target loci. In addition, it was shown that 
some of the fusion partners recruit Dot1L, a histone methyltransferase that trimethylates 
H3K79 and unregulates the expression of Hox genes. The recruitment of Dot1L is linked to 
the chromosomal translocation of MLL1 with AF4, AF9, AF10 and ENL. The corresponding 
mistargeting of Dot1L deregulates the expression of HoxA9 and Meis1 genes ultimatively 
causing abnormal embryonic development (Anglin & Song 2013; Daser & Rabbitts 2005; 
Krivtsov & Armstrong 2007; Muntean & Hess 2012). Furthermore, MLL proteins are 
frequently mutated in cancer, which can lead to loss-of-function or gain-of-function. MLL3 is 
one of the most frequently mutated PKMT present in glioblastoma, melanoma, pancreatic and 
breast cancer (Kandoth et al. 2013; Kudithipudi & Jeltsch 2014). A detailed biochemical 
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investigation of effects of somatic cancer mutations located in the SET domain of MLL1 and 
MLL3 on the enzymatic properties was performed in this thesis. 
1.12.1. MLL methyltransferases are associated with multi protein complexes 
The MLL histone lysine methyltransferase family associates with a large protein complex, 
which is necessary for the optimal methyltransferase activity of each enzyme. In yeast, Set1 
associates with a complex of proteins called COMPASS for “Complex of Proteins Associated 
with Set1”, also found as COMPASS-like complexes in D. melanogaster and mammalian 
cells. All COMPASS complexes contain WDR5 (Tryptophan-aspartate repeat protein-5), 
RBBP5 (Retinoblastoma-binding protein-5), ASH2L (Absent small homeotic-2-like) and 
DPY30 (Dumpy-30), which are homologs of Cps30, Cps20, Cps60 and Cps25 in yeast, 
respectively. Additionally, each MLL COMPASS-like subfamily has specific additional 
complex partners. For example, the SET1A/SET1B COMPASS-like complex contains 
Wdr82, related to Cps35 in yeast, which was shown to cross-talk with H2B 
monoubiquitination and helps to install H3K4 trimethylation. Menin is specific for MLL1/2-
COMPASS-like subfamily. It is a tumor suppressor that helps to localize to Hox genes, 
necessary for gene expression during development. The H3K27 demethylase UTX is a 
specific component for the MLL3/4 COMPASS-like structure. H3K27 methylation and H3K4 
methylation are known to have antagonistic roles. Methylation of lysine 4 on histone H3 leads 
to gene activation, while methylation on lysine 27 on the same histone tail has silencing 
effects. Demethylation of H3K27 by UTX further helps to maintain the activation mark of 
H3K4 introduced by MLL3/MLL4 COMPASS-like structure (Figure 8B) (Smith et al. 2011; 
Piunti & Shilatifard 2016). 
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Figure 8: Domain organization of yeast Set1 and mammalian MLL family proteins. A) All presented proteins contain the 
catalytical SET domain, followed by the postSET domain at the C-terminus. Yeast Set1 (Sc Set1) and human SET1A/B (Hs 
SET1A/B) have a RNA recognition (RRM) motif at the N terminus. MLL1-4 has several protein-protein interaction domains 
like plant homeodomain (PHD) finger and bromodomain (Bromo). The FYRC and FYRN domains are also present in MLL1 
to 4. In MLL1/2 these two domains are separated by a gap, whereas they are located next to each other in MLL3/4. 
Additionally, MLL1 and MLL2 contain a CxxC domain that has been shown to recruit to unmethylated CpG DNA sites and 
AT Hooks that helps to localize to specific target gene loci. B) Set1, the single H3K4 methyltransferase in yeast 
Saccharomyces cerevisiae, associates with a complex called COMPASS. Mammalian cells contain six homologous proteins 
viz. MLL1-4 and SET1A/B, which are all found associated with COMPASS-like homologous complex. All have in common 
the complex proteins WDR5 (Tryptophan-aspartate repeat protein-5), RBBP5 (Retinoblastoma-binding protein-5), ASH2L 
(Absent small homeotic-2-like) and DPY30 (Dumpy-30). Each MLL COMPASS-like subfamily has specific complex 
partners, like Wdr82 in SET1A/B, MENIN in MLL1/2 and UTX in MLL3/4. Figures are taken from (Smith et al. 2011). 
1.12.2. Structural rearrangement of the COMPASS-like complexes 
The crystal structure of MLL1 in complex with AdoHcy and a histone peptide substrate has 
shown that the active pocket of MLL1 has not the optimal conformation necessary for 
efficient methyl transfer from the cofactor AdoMet to the target lysine (Southall et al. 2009). 
Like other SET domain containing proteins, the active pocket of MLL1 consists of the 
preSET domain, SET domain (including SET-N, SET-I and SET-C) and the C-terminal 
postSET domain. Also, the essential residues of the active site are conserved and have an 
almost identical arrangement compared to other SET domain containing proteins. However, 
the orientation of the SET-I helix is different from highly active histone lysine 
methyltransferases like Dim5, which leads to a more open conformation. Southall et al. 
suggested a model in which the open conformation could close after binding of the complex 
partners WDR5, RBBP5 and ASH2L (WRA). The complex partners reorient the SET-I region 
and, thereby, a complete lysine binding channel is formed, where the target lysine chain is 
placed at a defined position for efficient methyl transfer (Southall et al. 2009). In 2016, Li and 
colleagues were able to resolve the crystal structure of MLL3 together with a minimized 
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structure of the RBBP5/ASH2L (RA) heterodimer and provided a two-step activation 
mechanism for MLL proteins (Li et al. 2016). In this study, measurements of the structural 
dynamics showed that the MLL proteins are highly dynamic without complex partners. By the 
addition of complex partners, a more stable catalytic competent conformation was achieved 
described as the first step for activation. In the second step, binding of the target substrate 
results in a rearrangement of the SET-I region that completes the hydrophobic tunnel (Avdic 
et al. 2011; Li et al. 2016; Southall et al. 2009).
1.12.3. Interaction between MLL and RBBP5/ASH2L heterodimer  
The crystal structure of MLL together with complex proteins has led to a much better 
understanding of the regulation of the methyl transfer process in MLL proteins. It was shown 
that MLL proteins primarily interact with RA heterodimer. When MLL is bound to the RA 
heterodimer, together with the cofactor product AdoHcy and H3 peptide, RBBP5 adopts an 
extended conformation, with a rigid coil conformation in the ASH2L binding motif (ABM) 
and two β-strands in the activation segment (AS) (Figure 9A). The interface of ASH2L and 
RBBP5 contains two arginine residues (R343 and R367) of ASH2L interacting via hydrogen 
bonds with Asp353, Glu349 and Glu347 of RBBP5. A strong interaction between RBBP5 and 
MLL3 is achieved through intermolecular β-sheet interactions between two β-strands located 
in the L-shaped AS domain of RBBP5 and β4 and β7 of MLL3. In addition, a conserved 
arginine residue located in the SET-I region of MLL proteins (e.g. R3864 of MLL1) plays an 
important role in the complex assembly, as it fits perfectly into an acidic pocket formed by 
RBBP5 and ASH2L, which is stabilized by the formation of five salt-bridges and a network of 
hydrogen bonds. Sequence alignments have shown that the amino acid residues responsible 
for the binding with complex partners are conserved within the MLL protein family, 
indicating that all MLL proteins have the same electrostatic network to form the MLL-RA 
assembly. Based on a mutational analysis, Li and colleagues could show that RA heterodimer 
interacts with all MLL proteins identically and the activation mechanism is conserved within 
the MLL family. 
1.12.4. Interaction between MLL and WDR5 
WDR5 is a scaffolding protein that serves as bridging molecule and stabilizes the interaction 
between the catalytic MLL enzymes and the RBBP5/ASH2L heterodimer. Knockdown of 
WDR5 in mammalian cells resulted in a global loss of H3K4me3. It also led to a decreased 
expression of Hox genes and problems during development and hematopoiesis (Wysocka et 
al. 2005). The crystal structure of WDR5 indicates that it folds as a seven-bladed tryptophan-
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aspartate (WD) repeat β-propeller and it binds MLL1 and RBBP5 at two well defined surface 
pockets, located at the opposite site of its β-propeller domain (Figure 9B) (Avdic et al. 2011). 
The MLL-WDR5-RBBP5 complex is stabilized by a network of hydrogen bonds and van der 
Waals interactions. RBBP5 interacts with WDR5 through three conserved amino acids valine-
aspartate-valine, known as VDV motif. This motif adopts a kink conformation and binds into 
a V-shaped cleft formed by two β-strands of WDR5. On the opposite side, WDR5 has an 
arginine binding cavity that interacts with a highly conserved WDR5-interacting-motif 
(WIN), located in the N-SET region of MLL proteins. The interaction between MLL1 and 
WDR5 is important for the core complex assembly and optimal methyltransferase activity. As 
already mentioned, MLL1 is often found as MLL1-AF9 fusion protein in ALL and AML 
patients. For treatment of leukemogenesis, scientists developed inhibitors, mimicking the 
WIN motif of MLL1. These inhibitors disrupt the interaction between MLL1 and WDR5 and 
by this decrease its catalytic activity. The inhibitor MM-102, was shown to inhibit the 
expression of HoxA9 and Meis-1. Further, it inhibits cell growth in leukemia cells carrying 
MLL1 fusion proteins (Karatas et al. 2013). MM-102 was also used in this thesis to study the 
inhibitory effect on somatic cancer mutations located in the SET domain of MLL1. 
1.12.5. Differences between MLL1 and the other MLL family proteins  
Previous studies have shown that MLL1 behave differently than other MLL proteins, 
regarding its methyltransferase activity (Li et al. 2016). Unlike all other MLL proteins, MLL1 
is dependent on WDR5 to exhibit full methyltransferase activity. The methyltransferase 
activity of MLL1 is increased by the addition of RA heterodimer, but the addition of WDR5 
further stimulates it, finally leading to the optimal methyltransferase activity. Compared to 
that, all other members of the MLL family are fully activated by the addition of RA alone and 
WDR5 is not necessary for further stimulation. Two amino acids (Asn3861 and Gln3867) 
located in the binding region of MLL1 to RA are necessary for these differences. MLL1 
contains a glutamine residue at position 3867, instead of a valine in the case of MLL3 that 
cannot fit into the well-defined pocket formed by MLL and RBBP5. At position 3861, MLL1 
contains asparagine, which cannot interact with the hydrophobic residues Leu339, Val343 and 
Tyr345 of RBBP5 surrounding a threonine at position 4803 in MLL3. This sequence 
differences weaken the interaction of MLL1 with the RA heterodimer such that WDR5 is 
needed as bridging factor to further stabilize the interaction.  
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Figure 9: Complex conformation of MLL-RA. A) Crystal structure of MLL3 SET domain (red) in complex with RBBP5 
(blue) and ASH2L (yellow). RBBP5 represents two β-strands located in the activation segment (AS) and a rigid coil located 
in the ASH2L binding motif (ABM). The crystal structure reveals the SPRY (SPIa and Ryanodine Receptor) domain located 
in the N terminus of ASH2L. B) WDR5 binds MLL and WDR5 at two distinct binding pockets, located at opposite sides of 
its β-propeller domain. Two β-blades (β5 and β6), which are necessary for the interaction between WDR5 and RBBP5 are 
highlighted. Carbon atoms of MLL1WIN peptide colored in cyan and RBBP5 371-380 colored in yellow. Figures are taken from 
(Avdic et al. 2011; Li et al. 2016). 
  
26
2. Aims of the study 
It was one general aim of this PhD thesis to investigate the substrate specificity of the SUV4-
20H1, SUV4-20H2, MLL1 and MLL3 PKMTs in detail. Depending on the results, it was 
planned to use the specificity data for the identification of novel non-histone substrates of all 
four enzymes. During the course of the work two examples of unexpected assignments of 
PKMT and methylated protein were published in which the methylation site did not fit to the 
specificity profile of the PKMT. It was one aim of this thesis to reinvestigate methylation of 
these substrates. Over the past decade, somatic mutations in PKMTs were discovered by 
genome-wide sequencing studies of cancer tissues. To check the role of these mutations in 
carcinogenesis, it was planned to investigate the effects of them on the enzymatic properties 
of the MLL proteins in detail. 
2.1. Specific goals and achievements of the project 
2.1.1. Substrate specificity analysis of the SUV4-20H1 and SUV4-20H2 enzymes 
Previous studies raised questions regarding the product and substrate specificity of SUV4-
20H1 and SUV4-20H2. A ~10 fold preference for monomethylated H4K20 substrate was 
reported by Southall et al. (2014), whereas a ~3 fold preference for H4K20me1 was observed 
by Wu et al. (2013). Both researchers identified that SUV4-20H enzymes only transfer one 
methyl group on H4K20me1 (Southall et al. 2014; Wu et al. 2013). Contrary, H4K20 
trimethylation was observed, when nucleosomes were used as substrates (Schotta et al. 2004). 
In this study, it was planned to perform peptide array methylation experiments and 
methylation of purified peptides in solution to solve this discrepancy. To get more insights 
into the different functions of these two paralogs, substrate specificity profile arrays of both 
enzymes should be analyzed and further used for the identification of potential non-histone 
targets in a proteome wide search. 
2.1.2. Identification of wrong assignments between PKMT and methylated target site 
In the course of this work, two examples of potential mis-assignments of protein methylation 
sites and PKMTs were published. ERK1 was reported to be trimethylated at K302 and K361 
by SUV4-20H1 (Vougiouklakis et al. 2015). This result was surprising, because it was 
reported that SUV4-20H1 uses an unmethylated target substrate to introduce trimethylation, 
which is not comparable with our results on histone H4 peptide substrates. In addition, the 
surrounding sequences of both target ERK1 lysines are not matching with the specificity 
profile of SUV4-20H1. The aim of this project was to verify methylation of ERK1 by SUV4-
20H enzymes at peptide and protein level using purified SUV4-20H enzymes. 
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Dhami et al. (2013) reported that SET8 dimethylates Numb at K158 and K163 (Dhami et al. 
2013). Also this finding was surprising, because it is known that SET8 is a strict 
monomethyltransferase. Comparison of the reported methylation sites of Numb with the 
substrate specificity of SET8 showed that the surrounding sequences of the predicted target 
lysine residues are not fitting. It was one aim of this project to confirm methylation of Numb 
by SET8 purified from E.coli and HEK293 cells at peptide and protein level. 
2.1.3. Substrate specificity analysis of MLL1 and MLL3 
The MLL protein family consists of 6 members: MLL1-4, SET1A and SET1B. They can be 
further classified in 3 subfamilies dependent on different enzymatic functions. MLL1/2 
catalyze trimethylation of H3K4 at promotors of specific genes, e.g. Hox genes. MLL3/4 are 
monomethyltransferases of H3K4 located at enhancers elements and SET1A/B catalyze 
genome-wide trimethylation of H3K4. All MLL proteins are associated with a multi protein 
complex to obtain full methyltransferase activity. One aim of this study was to determine the 
detailed substrate specificity of MLL1 and MLL3 in absence or presence of complex proteins 
to find out if the complex partners influence the specificity of MLL enzymes. Based on the 
resulting recognition motif, it was intended to identify possible non-histone substrates in the 
human proteome. 
2.1.4. Influence of somatic cancer mutations on the enzymatic properties of MLL1 
 and MLL3 
Genome-wide sequencing studies of cancer tissues uncovered several somatic mutations in 
PKMTs. Somatic cancer mutations can have various effects on the enzymatic properties of 
PKMTs including loss-of-function or gain-of-function phenotypes. In this project, it was 
planned to investigate the functional consequences of selected somatic cancer mutations in 
MLL1 and MLL3, using detailed biochemical analyses and by this improve our understanding 
of the role of these mutations and the corresponding PKMTs in carcinogenesis in general. 
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3. Materials and Methods 
This section describes only methods which have not been covered in manuscripts 1-4, 
provided in the attachment of this thesis. 
3.1. Cloning, Expression and Purification of Proteins 
The DNA sequences encoding the non-histone proteins were amplified from cDNA derived 
from HEK293 cells and cloned into the corresponding restriction sites of the pGEX-6p2 
vector (GE Healthcare) as GST fusion proteins. Detailed information about the non-histone 
substrates are listed in Table 1 and 2 in the results part. 
The C3882S mutation of MLL1 protein variants and the K to R mutations of TICRR and 
ZNF862 were introduced using a megaprimer PCR mutagenesis method. Mutagenesis was 
confirmed by restriction site digestion and followed by DNA sequencing. 
For protein expression E.coli BL21 Codon + cells (Novagen) were transformed with the 
corresponding plasmid and grown in Luria-Bertani media at 37°C until they reached an 
optical density at 600 nm of 0.6 to 0.8. Then, the cells were transferred to 20°C for 10 min 
and induced overnight by addition of 1 mM iso-propyl-beta-D-thiogalactopyranoside to the 
growth medium. The cells were harvested by centrifugation (5000 g). 
The GST-fusion proteins were purified as described (Dhayalan et al. 2011). 
3.2. Synthesis of peptide SPOT arrays 
Peptide arrays were synthesized on cellulose membrane using the SPOT synthesis method 
(Frank 2002) with a Autospot Multipep system (Intavis AG) by Dr. Srikanth Kudithipudi. 
Each spot contained approximately 9 nmol peptide (Autospot Reference Handbook, Intavis 
AG) and the successful synthesis of the peptides on the cellulose membrane was qualitatively 
confirmed by bromophenol blue staining. Data analysis and derivation of sequence motif and 
discrimination factor calculation was performed as described previously (Kudithipudi, 
Kusevic, et al. 2014; Rathert, Zhang, et al. 2008).
3.3. Peptide array methylation 
The peptide arrays were pre-incubated in methylation buffer (50 mM Tris/HCl pH 8, 200 mM 
NaCl, 5 mM MgCl2 and 3 mM DTT) for 5 min at 25°C. The arrays were then incubated for 
60 min at 25°C in methylation buffer containing 840 nM MLL1 SET protein or 50 nM 
MLL3-SET protein and 0.76 µM radioactive labeled AdoMet (Perkin Elmer). Afterwards, the 
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membranes were washed 5 times for 5 minutes with wash buffer (100 mM NH4HCO3 and 1% 
SDS) and finally incubated with Amplify NAMP100V solution (GE Healthcare) for 5 
minutes. The peptide arrays were exposed to HyperfilmTM high performance autoradiography 
films (GE Healthcare) in the dark at -80°C for 1-8 days. The autoradiography films were 
developed in Optimus TR developing machine. 
3.4. Protein methylation reaction 
Protein methylation was performed by incubating recombinant H3.1 (New England Biolabs) 
or non-histone protein substrates with MLL protein variants in the presence or absence of 
equimolar amounts of complex partners WDR5, RBBP5 and ASH2L in methylation buffer 
containing 50 mM Tris/HCl pH 8, 200 mM NaCl, 5 mM MgCl2 and 3 mM DTT, 
supplemented with 0.76 µM labeled [methyl-H3]-AdoMet (Perkin Elmer) for 2 h at room 
temperature. Afterwards, the methylation reactions were stopped by heating to 95°C for 5 min 
and the samples were separated on a 16% SDS PAGE gel. Then, the gels were dried, after 
soaked with Amplify NAMP100V solution (GE Healthcare) for 5 minutes. Subsequently, the 
gels were exposed to HyperfilmTM high performance autoradiography films (GE Healthcare) 
in the dark at -80°C for 1-8 days. The autoradiography films were developed in Optimus TR 
developing machine. 
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4. Results 
Lysine methylation is an important posttranslational modification, which is introduced by 
protein lysine methyltransferases. It affects many important processes of proteins including 
protein-protein interaction, protein localization and protein degradation, which are involved in 
the regulation of many biological processes. Over the last decades, many PKMTs and also 
protein lysine methylation sites were identified in the genomes and proteomes of many 
organisms in a very short time. While initially histones were considered the main targets of 
protein lysine methylation, more recently non-histone proteins were detected as possible 
substrates of methyltransferases. The understanding of the biological outcome of lysine 
methylation events is very complex. On each lysine residue up to three methyl groups can be 
transferred and, dependent on the methylation state and the methylated target site, lysine 
methylation leads to different effects, like transcriptional activation or repression if histone 
methylation is considered. 
To advance our understanding of the biological role of protein lysine methylation, it is a great 
challenge to connect a specific target site with the responsible methyltransferase. A good 
approach to tackle this challenge is to analyze the substrate specificity of PKMTs. This can be 
achieved by methylation of substrate specificity arrays, which allow the methylation of many 
different peptide substrates in competition within one experiment. This method provides 
detailed information about the specificity of an enzyme which is helpful for the identification 
of novel PKMT substrates in the human proteome. However, with increasing global interest 
in protein lysine methylation also wrong assignments between enzymes and target substrates 
were published, which could be sorted out with better knowledge of the substrate sequence 
preference of PKMTs. 
PKMTs also play a fundamental role in carcinogenesis. Expression changes of PKMTs were 
detected in cancers and in several cases somatic cancer mutations were identified in PKMTs. 
Since each of these mutations can have specific effects on the enzymatic properties, a detailed 
experimental examination of the effects of mutations in PKMTs is required for the better 
understanding of the role of these enzymes in cancer and the development of an effective 
therapeutic strategy. 
In this work, the substrate specificity of different protein lysine methyltransferases was 
investigated. Two examples of unexpected assignments of methylation events to PKMTs were 
studied and could be shown to represent wrong assignments. Furthermore, somatic cancer 
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mutations of MLL1 and MLL3 were identified and mutant specific effects on the enzymatic 
properties of these enzymes were described in detail. 
4.1. Specificity of the SUV4-20H1 and SUV4-20H2 protein lysine 
 methyltransferases and methylation of novel substrates 
(Manuscript 1 in the attachment of this thesis) 
Weirich S, Kudithipudi S, Jeltsch A. (2016). Journal of Molecular Biology, 2016 Jun 
5;428(11):2344-58. doi: 10.1016/j.jmb.2016.04.015. Epub 2016 Apr 20.
In human cells, two SUV4-20 paralogs, SUV4-20H1 and SUV4-20H2, catalyze the 
methylation of H4 at K20 and play an important role in heterochromatin formation. Both 
enzymes have overlapping and distinct biological effects. In this study, critical enzymatic 
properties of SUV4-20H1 and SUV4-20H2 (sometimes collectively abbreviated as SUV4-
20H) were investigated to get more insights into their different cellular functions. Previous 
published data showed slight disagreements with respect to the substrate and product 
specificity of the SUV4-20H enzymes. As described in 1.11., in vitro methyltransferase 
activity analyses of SUV4-20H1 and SUV4-20H2 have shown that both enzymes transfer one 
methyl group to monomethylated H4K20 peptide substrates (Southall et al. 2014; Wu et al. 
2013), but results differed in details. While Wu et al. (2013) observed a ~3 fold preference for 
monomethylated H4K20 substrate, Southall et al. (2014) reported that SUV4-20H enzymes 
prefer H4K20me1 by about 10 fold. In order to resolve these discrepancies, mouse SUV4-
20H1 and SUV4-20H2 were cloned as GST-fusion proteins and purified by affinity 
chromatography (manuscript 1, Figure 1a). Methylation of peptide arrays containing different 
modified forms of H4K20 peptide substrates indicated that both enzymes strongly prefer 
H4K20me1 as substrate (manuscript 1, Figure 1b). Methylation assays with soluble peptides 
showed a 10-fold higher preference of SUV4-20H1 for the monomethylated H4K20 peptide 
when compared with the unmethylated H4K20 peptide substrate. Similarly, SUV4-20H2 had 
a 28-fold higher activity on the H4K20me1 peptide than on the unmethylated H4K20 peptide 
(manuscript 1, Figure 1c). Further analysis of peptide methylation by SUV4-20H1/H2 using 
MALDI mass spectrometry failed to detect methyl transfer to the unmethylated peptide 
substrate. Methylation of the H4K20me1 substrate by SUV4-20H1 and H2 resulted in the 
appearance of a second peak with 14 kDa difference, which revealed the transfer of a single 
methyl group to the H4K20me1 peptide. Higher methylation states were not introduced by 
SUV4-20H enzymes even after long incubation times (manuscript 1, Figure 2). These peptide 
32
methylation experiments imply that SUV4-20H1 and SUV4-20H2 introduce one single 
methyl group on the monomethylated H4K20 peptide substrate in vitro. 
Even if SUV4-20H1 and SUV4-20H2 have the same product and substrate specificity with 
respect to the methylation state of the target lysine, different biological functions can be 
explained by sequence specific interactions of each enzyme with the substrate peptide. 
Substrate specificity profile analysis of both paralogs were performed to analyze their specific 
interaction with the substrate peptide using the monomethylated H4 (13-27) sequence as 
template (Figure 10). The substrate specificity peptide arrays were methylated by SUV4-
20H1 or SUV4-20H2 using radioactively labeled AdoMet. The methyl transfer to the 
immobilized peptide was detected by autoradiography. As all the peptides are methylated in 
competition, the observed methylation signal directly reflects the preference of SUV4-20H 
enzymes towards a specific peptide sequence. The data revealed that SUV4-20H1 prefers a 
(RY)-Kme1-(IVLM)-(LFI)-X-D sequence motif, while SUV4-20H2 recognizes a slightly 
different X-Kme1-(IVLMK)-(LVFI)-X-(DEV) sequence motif (manuscript 1, Table 1). 
Overall the specificity profile analysis demonstrates that the SUV4-20H enzymes interact 
with the same residues of H4 tail, but SUV4-20H1 is more specific and accepts only a smaller 
number of alternative residues at the corresponding positions than SUV4-20H2. Compared to 
SUV4-20H2, SUV4-20H1 is more specific at the -1 and +4 positions of the substrate 
(considering the target lysine as position 0). At position -1, SUV4-20H1 is only active with 
the canonical arginine, whereas in the case of SUV4-20H2 arginine can be exchanged by 
several amino acids at this position. At position +4, SUV4-20H1 only recognizes aspartic 
acid, whereas SUV4-20H2 also accepts E and V (manuscript 1, Figure 3 and 4). These 
deviations suggest that there might be differences between both enzymes regarding the 
recognition of non-histone targets. 
Based on the more relaxed substrate recognition motif of SUV4-20H2, which also includes all 
potential substrates of SUV4-20H1, the Phosphosite PLUS database was used to search for 
potential novel methylation substrates of these enzymes, because it also contains several 
protein lysine methylation events identified in proteomics studies. 7 novel substrates were 
identified, which were known to be methylated within the SUV4-20H core sequence 
recognition motif by a not yet identified PKMT (manuscript 1, Table 2). Peptide array 
methylation experiments showed that one protein (CASZ1) can be methylated by SUV4-
20H1 and three proteins (CASZ1, OIP5 and CENPU) by SUV4-20H2 (manuscript 1, Figure 5 
and Suppl. Figure S1). 
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
Figure 10: Substrate specificity analysis of SUV4-20H1 and SUV4-20H2. A+B) Three independent peptide array 
methylation experiments were conducted with SUV4-20H1 or SUV4-20H2 and the data were averaged after normalizing the 
full activity to 1. The activity is displayed in the grey scale as indicated. The horizontal axis represents the template sequence 
(H4 13-27) and the vertical axis indicates the residues that were sequentially introduced at the position corresponding to the 
row. The target lysine H4K20 was monomethylated (Km). (Taken from manuscript 1, Figure 3b and Figure 4b) 
Vougiouklakis et al. (2015) reported recently, that ERK1 is methylated by SUV4-20H1 at 
K302 and K361 (Vougiouklakis et al. 2015). As described in 1.11.2., the surrounding 
sequences of both lysine residues are not fitting to the identified substrate recognition motif of 
SUV4-20H enzymes. To proof methylation of ERK1 by SUV4-20H enzymes, methylation 
reactions at peptide and protein level were performed. Methylation experiments on peptide 
arrays containing different methylation states of the predicted target lysine as well as K to A 
mutants as negative controls showed no methylation signal (manuscript 1, Figure 6). Also at 
the protein level, methylation of GST fused ERK1 or isolated ERK1 by the SUV4-20H 
enzymes could not be detected (Figure 11). These findings suggest that the reported 
methylation of ERK1 by SUV4-20H1 is a wrong assessment of PKMT and target. This 
finding was important, because methylated ERK1 was reported to play a central role during 
carcinogenesis and its connection to SUV4-20H enzymes could lead to pointless follow up 
studies and wrong therapeutic approaches. 
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Figure 11: In vitro protein methylation of ERK1 by SUV4-20H enzymes. A) Coomassie stained SDS-PAGE gel showing the 
proteins used in the methylation assay shown in panel B. SUV4-20H1 and GST fused ERK1 protein are labeled with black 
and red asterisks. B) SUV4-20H proteins were incubated with radioactively labeled AdoMet in the methylation buffer in the 
absence and presence of GST-ERK1 and methylation was analyzed by autoradiography. Sizes of proteins are indicated as 
described in A. C) Coomassie stained SDS-PAGE of GST cleaved ERK1 protein (indicated with the red asterisk), GST and 
uncleaved ERK1 (indicated with the black asterisk) were loaded as controls. SUV4-20H proteins were also loaded to indicate 
the protein sizes. D) SUV4-20H proteins were incubated with radioactively labeled AdoMet in the methylation buffer in the 
absence and presence of cleaved ERK1 and methylation was analyzed by autoradiography. The sizes of SUV4-20H1 and the 
cleaved ERK1 protein are indicated with black and red asterisks. A longer film exposure of this gel is shown in manuscript 1 
Suppl. Fig. 2. (Taken from manuscript 1, Figure 7)
4.2. Investigation of the methylation of Numb by the SET8 protein lysine 
 methyltransferase 
(Manuscript 2 in the attachment of this thesis) 
Weirich S, Kusevic D, Kudithipudi S & Jeltsch A. (2015). Scientific Reports, 2015 Sep 
22;5:13813. doi: 10.1038/srep13813. 
Compared to SUV4-20H1 and SUV4-20H2, SET8 is a highly specific H4K20 
monomethyltransferase with a long recognition motif extending from R17 to R23 on H4 [R17-
H18-(R19KY)-K20-(V21ILFY)-(L22FY)-R23] in which it tolerates only few alternative residues 
at the positions -1, +1 and +2 (considering the target lysine as position 0) (Figure 12A boxed) 
(Kudithipudi et al. 2012). Like other protein lysine methyltransferases, SET8 was also found 
to methylate non-histone targets and the tumor suppressor protein p53 was the first identified 
non-histone target of SET8. Recently it has been reported, that SET8 dimethylates Numb 
protein at lysine 158 and 163 (Dhami et al. 2013). Due to discrepancies at least at 4 out of 6 
positions between the sequence recognition motif of SET8 and the surrounding sequences of 
the predicted target lysines (K158 and K163) in Numb (Figure 12A), a further investigation of 
Numb methylation by SET8 was performed in this thesis. 
Peptide methylation experiments using radioactively labeled AdoMet showed that SET8 
cannot methylate the predicted target lysine residues K158 and K163, because only very weak 
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radioactive signals were observed and lysine to alanine mutations of these reported target sites 
did not lead to a loss of the radioactive signal (manuscript 2, Figure 2A). To further analyze, 
if the weak observed signals were due to binding of the SET8-AdoMet complex to these 
peptides or if another amino acid residue was methylated, mutational scanning peptide arrays 
of the Numb (151-165) and (156-170) peptides were prepared, in which each individual 
peptide residue was exchanged to alanine or serine if the original residue was alanine. 
Incubation of these arrays with SET8 indicated that SET8 probably catalyzes a weak cysteine 
methylation (manuscript 2, Figure 2B), a side reaction that was already reported for other 
PKMTs like MLL1 (Patel et al. 2014). To further investigate Numb methylation by SET8 at 
protein level, the Numb protein domain containing the reported methylation targets (residues 
12-272) was overexpressed as GST fusion protein in E.coli and purified by affinity 
chromatography. In vitro methylation assays were performed and clear methylation signals 
were detected with the positive controls H4 and p53, but no methylation of Numb was 
observed (Figure 12 B/C). We then noticed that for their in vitro methylation reactions, 
Dhami et al. used recombinant SET8 protein purified from human cells by 
immunoprecipitation. As SET8 purified from human cells might contain posttranslational 
modifications or interactors influencing its activity and specificity might be copurified, 
methylation reactions were repeated using recombinant YFP-SET8 purified from HEK293 
cells after transient overexpression. However, even using YFP-SET8 preparations, no 
methylation of Numb was detected (manuscript 2, Figure 4). In summary, in this study I could 
not observe methylation of Numb peptide or Numb protein by SET8 overexpressed and 
purified from E.coli or HEK293 cells. Therefore, more evidence is needed to support the 
claim by Dhami et al. and the reported downstream results (like the reported influence of 
Numb methylation on its interaction with p53 and subsequent effects on apoptosis) should be 
taken with care. 
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Figure 12: Sequence comparison and protein methylation of histone H4, p53 and Numb. A) The substrate specificity profile 
of SET8 was adopted from Kudithipudi et al. (2012) (boxed). The upper row represents the amino acid sequence of the H4 
tail surrounding K20 (printed in green), the lower row specifies the other amino acids that are also accepted at the 
corresponding position (printed in blue). Below, sequence alignment of the H4, p53 and Numb target lysine residues (Taken 
from manuscript 2, Figure 1) B) Coomassie BB stained SDS polyacrylamide gel of the purified GST-Numb, GST-p53 and 
recombinant H4 used as methylation substrates. The corresponding bands of H4, GST-Numb and GST-p53 are labeled by 
blue, red and green asterisks. (Taken from manuscript 2, Figure 3A) C) Methylation of GST-Numb, GST-p53 and H4 with 
recombinant SET8. The positions of the corresponding protein bands are indicated as described in panel B. Methylation 
signals from H4 and GST-p53 were detected, whereas no methylation signal was visible for GST-Numb. (Taken from 
manuscript 2, Figure 3B) 
4.3. Studies with MLL protein lysine methyltransferase family members 
The mammalian mixed-lineage leukemia (MLL) protein family consists of 6 members: 
MLL1-4, SET1A and SET1B (Piunti & Shilatifard 2016). Three pairs of MLL proteins form 
three subfamilies representing the homologs of the three H3K4 Drosophila melanogaster
methyltransferases SET1, TRX and TRR. All MLL proteins catalyze the methylation of 
H3K4 and thereby play an important role in early development and hematopoiesis (Ansari et 
al. 2009; Smith et al. 2011). Previous studies have shown that the different MLL PKMTs have 
non-overlapping functions. MLL1/2 introduce H3K4 trimethylation at promotors of active 
genes, MLL3/4 catalyze H3K4 monomethylation at active enhancers and SET1A/B introduce 
genome-wide H3K4 trimethylation (Cheng et al. 2014). Each MLL protein has its specific 
domain architecture, whereas the MLL subfamilies are similar constructed (see Figure 8A in 
the introduction of this thesis). In cells, the MLL proteins are part of a large protein complex 
also containing the WDR5 (Tryptophan-aspartate repeat protein-5), RBBP5 (Retinoblastoma-
binding protein-5), ASH2L (Absent small homeotic-2-like) and DPY30 (Dumpy-30) core 
members, which are needed to achieve optimal methyltransferase activity (Avdic et al. 2011; 
Li et al. 2016). Li et al. reported that the MLL proteins primarily interact with the RA 
heterodimer and WDR5 serves as a bridging molecule between MLL and RA. DPY30 is 
another component, which is common for all MLL complexes. However, previous studies 
have shown that it only interacts with ASH2L and increases the overall reaction rate only by 
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2-fold compared to MLL-WRA (Patel et al. 2009). In this study two MLL proteins, MLL1 
and MLL3, which are members of different subgroups of the MLL proteins, were selected and 
further analyzed. My main interest was to investigate the individual sequence specificities of 
both paralogs, as it was already shown that they catalyze H3K4 methylation at distinct 
genomic regions. Moreover, the specificity profiles of MLL1 and MLL3 were used to search 
for additional possible substrates of both enzymes.
In addition, somatic cancer mutations of MLL proteins have been found in several cancer 
tissues. In this thesis, identified somatic cancer mutations located in the SET domains of 
MLL1 and MLL3 were experimentally investigated regarding their effects on the enzymatic 
activity in presence or absence of the WRA complex partners. Differences in the substrate 
specificity of MLL1 cancer mutants were studied on MLL1 specific non-histone targets. 
Finally, potential effects of somatic cancer mutations on the product methylation pattern were 
further investigated for MLL1 and MLL3 in this thesis. 
4.3.1. Investigation of the MLL1 protein lysine methyltransferase 
4.3.1.1. Somatic cancer mutations in MLL1 induce conformational changes and modulate 
 the enzymatic activity 
(Manuscript 3 in the attachment of this thesis) 
Weirich S, Kudithipudi S & Jeltsch A. (2017). Molecular Oncology. 2017 Apr;11(4):373-387. 
doi: 10.1002/1878-0261.12041. Epub 2017 Mar 10.
The protein lysine methyltransferase MLL1 (KMT2A) is a large, 3969 amino acids long 
protein which catalyzes trimethylation of H3K4 at promotors of active genes (Cheng et al. 
2014; Smith et al. 2011). Within the MLL protein family, MLL1 is one of the most studied 
members, because it has been found to be frequently involved in chromosomal translocations 
in acute lymphoid and myelogenous leukemia, which lead to dysregulation of developmental 
genes like HoxA9 and Meis1 (Anglin & Song 2013; Daser & Rabbitts 2005; Krivtsov & 
Armstrong 2007; Muntean & Hess 2012). Beside chromosomal translocation several somatic 
cancer mutations have been identified in MLL1, which have not been studied yet 
(Kudithipudi & Jeltsch 2014). Using the COSMIC database (August 2016), 665 mutations 
were reported in MLL1, out of them 78% missense and 22% non-sense mutations and frame-
shifts. To better understand the effect of somatic cancer mutations, four mutations in the SET 
domain were selected and studied here in detail, which are located close to the peptide, 
AdoMet or complex partner interaction site and, therefore, could have direct effects on 
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enzymatic properties of MLL1: R3841W (found in prostate cancer) (Barbieri et al. 2012), 
R3864C (found in lung cancer) (Muzny et al. 2012), S3865F (found in skin cancer) (Durinck 
et al. 2011) and R3903H (found in large intestine cancer) (Muzny et al. 2012) (manuscript 3, 
Figure 1). The catalytic SET domains of MLL1 wildtype and all four MLL1 cancer variants 
were cloned as GST-fusion proteins and purified via affinity chromatography (manuscript 3, 
Figure 2A). Circular dichroism spectroscopy (CD) measurements of the four purified MLL1 
cancer variants showed that all mutant proteins have similar fold like wildtype, except 
R3841W (manuscript 3, Figure 2B). Changes in the CD spectra of R3841W could be due to 
changes in conformation, folding or aggregation state. To assess the catalytic activity of the 
purified proteins, methylation experiments were performed. Two mutants (R3864C and 
R3841W) had an increased activity in comparison to wildtype MLL1, whereas S3865F 
showed a reduced methyltransferase activity and R3903H was inactive (manuscript 3, Figure 
2C). To test the stimulatory effect of the WRA complex members on the methyltransferase 
activity of MLL1, peptide methylation assays were performed. As expected, a strong 
stimulation of the methyltransferase activity of MLL1 was detected in presence of the WRA 
complex. Further methylation experiments were implemented to analyze the catalytic 
properties of all 4 cancer mutants in presence of equimolar amounts of complex partners 
(manuscript 3, Figure 2D). The results demonstrated that R3903H was inactive also in the 
presence of the WRA complex proteins. MLL1 wildtype and S3865F showed higher 
methyltransferase activity in presence of complex partners, but the overall catalytic activity of 
S3865F was lower. Interestingly, two of the mutants, R3864C and R3841W, displayed a 
reduced activity in the presence of complex partners, which represents a pronounced change 
in properties when compared to wildtype MLL1 (Figure 13). This result indicates that both 
enzymes are not dependent on complex partners to achieve their full catalytic activity, as they 
were already fully active in isolated form. 
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Figure 13: Methylation activity of MLL1 cancer variants in complex with the WRA proteins. Recombinant H3 was 
methylated by MLL1 and mutant proteins in absence or presence of the WRA complex. A) Autoradiographic image of an 
SDS polyacrylamide gel. Samples with (+) or without (-) complex partners were loaded next to each other. The methylation 
signal of H3 is indicated. * represents automethylation of the MLL1 mutant proteins. B) Quantitative analysis of the H3 
methylation signal using duplicate experiments. The activity of isolated MLL1 was set to 1 and the other signals were 
normalized accordingly. Error bars indicate the standard error of the mean. (Taken from manuscript 3, Figure 3)
In this respect, the question arose if the different MLL1 variants were interacting properly 
with the complex partners. While MLL2-4 are mainly dependent on the interaction with RA 
heterodimer to be fully active (Li et al. 2016; Cao et al. 2014; Southall et al. 2009), MLL1 
requires WDR5 as a bridging molecule to interact with RA and achieve full methyltransferase 
activity (Li et al. 2016). Interaction between MLL1 and WDR5 is based on the WIN motif, 
located in the N-SET region of MLL proteins (Patel et al. 2009). The WIN motif contains an 
arginine residue that is conserved within the MLL protein family. Previous studies showed 
that this arginine is crucial for the complex assembly as exchange of R3765 against alanine 
abolishes the interaction between MLL1 and WDR5 (Patel et al. 2008). Small molecular 
inhibitors mimicking this WIN sequence (MM-102 inhibitor) were investigated to disrupt the 
MLL1-WDR5 interaction. These inhibitors can be used as a new therapeutic approach to 
reduce MLL1 hyperactivity in leukemia (Cao et al. 2014; Karatas et al. 2013; Li et al. 2016). 
The WDR5 interaction was confirmed for all 4 somatic cancer mutations with GST pull-down 
experiments, using the MM-102 inhibitor to disrupt persisting interactions as additional 
control (manuscript 3, Figure 4A). This result was expected as the mutation did not include 
residues in the WIN motif. In the next step, AlphaScreen assay measurements were used to 
investigate the interaction between MLL1 and the RA or WRA complexes. For all MLL1 
variants similar AlphaScreen signals were obtained, indicating that all MLL1 proteins interact 
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similarly with the RA heterodimer. The AlphaScreen signals were increased with the WRA 
complex, in agreement with the fact that WDR5 further stabilizes the interaction between RA 
and all MLL1 protein variants. These findings demonstrate similar interactions of all MLL 
somatic cancer mutations with the RA heterodimer (manuscript 3, Figure 4B). Altogether, 
these interaction studies confirmed that the mutations have no effect on the complex 
formation and altered complex formation cannot be the reason for changes in the catalytic 
activity of the MLL1 mutants. 
To further analyze the effects of each complex member on the MLL1 activity, methylation 
experiments were carried out using all individual, binary and ternary combination of complex 
partners together with the MLL1 proteins. Main differences were detected when the RA 
heterodimer was added to the MLL1 protein variants. The MLL1 wildtype methyltransferase 
activity was stimulated by the addition of RA heterodimer and further stimulation was 
achieved by the addition of WDR5. In contrast to that, addition of the RA heterodimer to the 
R3864C mutant led to a strong inhibition of the methyltransferase activity. When WDR5 was 
added to the R3864C-RA complex an increase in activity was detected, but the final activity 
of the R3864C-WRA complex was still lower than that of isolated R3864C. In the case of 
R3841W, the addition of RBBP5, ASH2L and RA heterodimer caused reductions in the 
methyltransferase activity, but addition of WDR5 to the R3841W-RA complex increased the 
activity to the same level like isolated R3841W (manuscript 3, Figure 5). 
Finally, the inhibitory effect of MM-102 on the methyltransferase activity of the different 
MLL1 mutants was investigated. Inhibition was detected in the case of MLL1 wildtype and 
S3865F, whereas no effect was observed with R3864C and R3841W (Figure 14). This result 
is in agreement with the previously described biochemical data, which demonstrate that the 
methyltransferase activity of MLL1 and S3865F is dependent on the interaction with WRA. 
In contrast, R3864C and R3841W exhibit full methyltransferase activity in absence of 
complex partners and because of this they are not affected by the inhibitory effect of MM-102 
on the MLL1-WDR5 interaction. In summary, these results demonstrate that the selected 
somatic cancer mutations either increase or reduce the activity of MLL1. Also the dependency 
on complex partners to achieve full methyltransferase activity was changed. Moreover, these 
data illustrate MM-102 cannot be used as universal MLL1 inhibitor, because no effect was 
detected with R3864C and R3841W. More generally these data show that individual 
biochemical investigation for each mutant is necessary for the development of therapeutic 
drugs. 
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Figure 14: Inhibition of the MLL1 proteins by MM-102. A) Recombinant histone H3 was methylated by MLL1 cancer 
variants together with WRA complex in the presence and absence of inhibitor. The methylation signal of H3 is shown. 
Different exposure times are indicated. B) Quantitative analysis of H3 methylation signals using duplicates of experiments. 
For better visualization of the inhibitory effect by MM-102, the activities of the MLL1 mutants were normalized to the 
corresponding activity without inhibitor treatment. The error bars indicate the standard error of the mean. (Taken from 
manuscript 3, Figure 6) 
4.3.1.2. Specificity analysis of MLL1 
Lysine methylation is an important epigenetic mark with an essential role in many biological 
processes. With the identification of non-histone proteins as possible substrates for many 
lysine methyltransferases like SET8, SET7/9, SMYD3, G9a and NSD1/2, lysine methylation 
gained even more importance (Fu et al. 2016; Rathert, Dhayalan, Murakami, et al. 2008; 
Kudithipudi, Lungu, et al. 2014; Kudithipudi et al. 2012; Dhayalan et al. 2011). Up to date, 
many methylation sites have been identified in proteome-wide studies, but the responsible 
methyltransferases are often unknown. Conversely, for many protein lysine 
methyltransferases the complete list of all relevant substrates has not been identified yet. In 
this chapter, substrate specificity analysis was used to investigate the specific interaction of 
MLL1 with the substrate peptide and search for novel substrates for MLL1. 
4.3.1.2.1. Substrate sequence specificity of MLL1 
To investigate the substrate specificity of MLL1 in detail, a peptide library was synthesized 
on a cellulose membrane using the SPOT synthesis method and methylated by MLL1. The 
libraries consisted of 320 individual peptides, in which each peptide contains an exchange of 
a single amino acid of the H3 (1-15) sequence against any of the 20 natural amino acids. Due 
to that the specific influence of each amino acid at every position of the substrate peptide on 
enzymatic activity can be analyzed in detail.  
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Substrate specificity peptide arrays were methylated by MLL1 using radioactively labeled 
AdoMet as described in chapter 4.1. Two independent methylation experiments were 
normalized and average methylation levels were calculated together with the standard 
deviation (SD) for the methylation activity on each peptide (Figure 15A). The distribution of 
errors shows that the experiments were highly reproducible. 93% of the peptides showed an 
SD smaller than ± 20%, 11 peptides had an SD between 20-30% and 7 peptides between 30-
40% (Figure 15B). The substrate specificity profile indicates that MLL1 discriminates 
residues of the H3 sequence from A1 to R8. High specificity was observed at position -2 and 
+4. At position -2, MLL1 only tolerates the canonical arginine, whereas at position +4 it 
weakly accepts cysteine or tyrosine, beside the canonical arginine. At -1 position, MLL1 
mainly interacts with hydrophobic residues (I, L, F, W, Y). MLL1 has a high preference for 
isoleucine or valine and it weakly accepts alanine and cysteine at position +2, in addition to 
the canonical threonine. In summary, the following substrate recognition motif was identified: 
A(PRFWY)-R-T(ILFWY)-K-Q(RHMFWY)-T(IVAC)-X-R(CY) 
Figure 15: Substrate specificity analysis of MLL1. A) Two independent peptide array methylation experiments were 
performed with MLL1 and the data were averaged after normalizing the full activity to 1. The activity is displayed in a grey 
scale as indicated. The horizontal axis represents the template sequence (H3 1-15). Each residue was exchanged against all 20 
natural amino acid residues as indicated by the vertical axis. B) Distribution of standard errors of the mean of MLL1 activity 
on all peptides tested in the two independent assays. 
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4.3.1.2.2. Methylation of potential non-histone substrates 
The substrate specificity analysis showed that MLL1 accepts several other residues at many 
positions of the target sequence, in addition to the residues in the original sequence of H3. 
Because of that, the identified substrate recognition motif was used to search for potential 
novel non-histone targets in the human proteome using Scansite (Obenauer et al. 2003). 98 
potential new peptide substrates containing the predicted sequence motif were found (Table 4, 
see appendix). To investigate if these targets can be methylated by MLL1, 15 amino acid long 
peptides with the target lysine at the center were synthesized on a cellulose membrane, 
including H3 (1-15) as positive control and H3K4A as negative control. The peptide array 
was incubated with MLL1 in a reaction mixture containing radioactively labeled AdoMet and 
the methyl transfer was detected by autoradiography. The data showed that 23 out of 98 
putative non-histone targets were methylated on the peptide array (Figure 16 and Table 4).  
Figure 16: Screening of MLL1 non-histone peptide substrates. The peptide array was methylated with MLL1 in presence of 
radioactively labeled AdoMet. The transfer of the methyl group to the immobilized peptides was detected by 
autoradiography. Target information is listed in Table 4.
To further analyze the methylation of the validated peptide substrates at protein level, 15 of 
them were selected and cloned as GST fusion proteins (Table 1). 10 out of 15 targets were 
successfully cloned. Afterwards, these targets were overexpressed and purified by affinity 
chromatography. Out of 10 target protein domains, 8 could be successfully overexpressed and 
purified (Figure 17A). 
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Table 1: Selected non-histone targets from the peptide array (Figure 16), which were further analyzed. 
Swiss 
Prot. Nr. 
Original name Name Synonyme Sequence Protein-
length 
MW
(kDa)
Target K 
position 
A3 Q9BR61 ACBD6_HUMAN
ACBD6 = Acyl-CoA-
binding domain-
containing protein 6 
ACBD6 LYLYARYKQVKVGNC 282 31 73 
A14 Q9H159 CAD19_HUMAN
CDH19 = Cadherin-
19 
CDH19 NELGPRFKRLACMFG 772 87 759 
A16 A6NFT4 CC42B_HUMAN
CCDC42B = Coiled-
coil domain-
containing protein 
42B 
CCDC42B ARLQRRLKRLEPCAR 308 36 138 
A17 P22674 CCNO_HUMAN CCNO= Cyclin-O CCNO EVHPPRVKQLLALCC 350 38 198 
B1 Q7Z2Z1 CO042_HUMAN TICRR= Treslin TICRR LRRSPRIKQLSFSRT 1910 211 1019 
B2 O15263 DEFB2_HUMAN
DEFB4A= Beta-
defensin 4A 
DEFB4A VFCPRRYKQIGTCGL 64 7 48 
B3 Q6QHC5 DEGS2_HUMAN
DEGS2 = 
Sphingolipid 
delta(4)-
desaturase/C4-
hydroxylase DES2 
DEGS2 LGPYARVKRVYRLAK 323 37 313 
B12 O60258 FGF17_HUMAN
 FGF17= Fibroblast 
growth factor 17 
FGF17 SAPTRRTKRTRRPQP 216 25 207 
B19 O00219 HAS3_HUMAN
HAS3= Hyaluronan 
synthase 3 
HAS3 LSLGYRTKYTARSKC 553 63 332 
C2 Q01113 IL9R_HUMAN
 IL9R= Interleukin-9 
receptor 
IL9R FKLSPRVKRIFYQNV 521 57 298 
D5 P11086 PNMT_HUMAN 
PNMT= 
Phenylethanolamine 
N-methyltransferase 
PNMT RQLRARVKRVLPIDV 282 31 152 
D7 Q09MP3 R51A2_HUMAN 
RAD51AP2= 
RAD51-associated 
protein 2 
RAD51 LSRKARIKQLHPYLK 1159 134 1141 
D18 Q9NYW4 TA2R5_HUMAN 
TAS2R5= Taste 
receptor type 2 
member 5 
TAS2R5 IMGIPRVKQTCQKIL 299 35 280 
E5 Q5VYS8 TUT7_HUMAN 
 ZCCHC6= Terminal 
uridylyltransferase 7 
ZCCHC6 SAIDPRVKYLCYTMK 1495 171 1145 
E16 O60290 ZN862_HUMAN 
 ZNF862= Zinc finger 
protein 862 
ZNF862 GDGPRRIKRTYRPRS 1169 132 457 
For methylation of the purified target protein domains, roughly equal amounts of each protein 
was incubated with the MLL1 SET domain in the presence of radioactively labeled AdoMet. 
As positive control recombinant H3 was included. To check for MLL1 automethylation, 
MLL1 was incubated in reaction buffer without including any additional substrate. After the 
methylation reaction, the samples were loaded on a 16% SDS gel and methyl transfer was 
detected by autoradiography. The result showed a strong automethylation signal of MLL1, 
because a methylation signal was observed at the size of the MLL1 SET domain even when 
no additional substrate was included in the methylation reaction. As many of the non-histone 
protein domains had nearly the same size as the MLL1 protein, the automethylation signal of 
MLL1 potentially overlapped with the substrate methylation signal making them more 
difficult to detect. For two substrate proteins, TICRR and ZNF862, clear methylation signals 
were observed. However for further analysis, the next step was trying to prevent or at least 
reduce the automethylation of MLL1 to increase the sensitivity of the detection of substrate 
protein methylation. 
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Figure 17: Methylation of MLL1 non-histone candidate substrate proteins. A) 16% SDS gel of MLL1 with all selected non-
histone proteins (TICRR, PNMT, ZNF862, DEGS2, ACBD6, HAS3, CCNO and RAD51) serving as loading control of the 
methylation experiments. B) Methylation of all proteins by MLL1. The corresponding bands of the expected size are labeled 
with asterisk. The methylation of recombinant H3, automethylation of MLL1 and exposure times are indicated. 
In 2014, Patel et al. identified that MLL1 undergoes automethylation at cysteine 3882 and 
they reported that an exchange of cysteine at position 3882 against serine prevents this 
reaction (Patel et al. 2014). Therefore, site directed mutagenesis was performed to create the 
MLL1 C3882S mutation in the GST-SET domain protein. In parallel, the C3882S mutation 
was also introduced into the MLL1 R3841W, S3865F and R3864C mutants. Successful 
mutagenesis was confirmed in all cases by sequencing. Afterwards, the MLL1 protein 
variants were overexpressed and purified by affinity chromatography (Figure 18A). To test 
automethylation, equal amounts of the original MLL1 wildtype and cancer mutants and the 
corresponding C3882S mutants were incubated with recombinant H3 in presence of 
radioactively labeled AdoMet. Methylated samples were separated via SDS-PAGE and 
transfer of the methyl group to the target lysine was analyzed by autoradiography. 
In Figure 18A, the upper band at 55 kDa represents the automethylation of the MLL1 protein 
variants, whereas the methylation signal at 15 kDa corresponds to methylation of the target 
substrate H3. The cysteine 3882 to serine mutation resulted in a reduction of automethylation 
of MLL1, R3841W and S3865F. In the case of the R3864C/C3882S double mutant, no loss of 
automethylation was detected (Figure 18A). One possible reason for that could have been that 
the introduced cysteine at position 3864 could be a new point of automethylation in this 
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MLL1 mutant. For all MLL1 proteins methylation of recombinant histone H3 was detected. 
Methylation of H3 by MLL1 C3882S was weaker compared to the methylation of H3 by 
wildtype MLL1. A similar decrease in activity on H3 was observed for all MLL1 C3882S 
somatic cancer mutants. No methylation of H3 was detected with MLL1 S3865F/C3882S, but 
after long exposure of the autoradiogram, H3 methylation by this protein variant was 
confirmed (Figure 19B). As shown previously, the somatic cancer mutations MLL1 R3864C 
and MLL1 R3841W exhibited higher methyltransferase activity on H3, whereas MLL1 
S3865F was less active compared to MLL1 wildtype (Figure 18A).  
To answer the question if cysteine at position 3864 is a new point of automethylation, another 
double mutant was cloned containing a glutamine at position 3864 and a serine at position 
3882. After the confirmation of successful cloning by sequencing, the MLL1 
R3864Q/C3882S protein was overexpressed and successfully purified (Figure 18B). Similar 
amounts of MLL1 R3864C/C3882S and MLL1 R3864Q/C3882S were used for methylation 
of recombinant H3. As control MLL1 wildtype and MLL1 C3882S was included. After the 
methylation reaction, the samples were separated via SDS-PAGE (Figure 18B). For both 
proteins, MLL1 C3882S and MLL1 R3864Q/C3882S, loss of automethylation was observed 
and also H3 methylation was identified, which means that both proteins were still active. With 
this result it was confirmed that the cysteine residue at position 3864 can be automethylated in 
the R3864C mutant. 
Figure 18: MLL1 automethylation assays. A) 16% SDS gel of MLL1 wildtype and MLL1 somatic cancer mutants with the 
corresponding C3882S mutant showing that roughly equal protein amounts of all MLL1 protein variants were used for 
methylation. B) 16% SDS gel of MLL1 wildtype (WT), MLL1 C3882S, MLL1 R3864C/C3882S and MLL1 
R3864Q/C3882S showing that roughly equal protein amounts of all MLL1 protein variants were used for methylation. 
Methyl transfer was detected by autoradiography. The corresponding bands of the expected size are labeled with asterisk. 
Exposure times are indicated. a= automethylation of MLL1; b= methylation of recombinant H3.
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As described above, it was shown that MLL1 only exhibits full methyltransferase activity, 
when it is associated with its complex partners WDR5, RBBP5 and ASH2L. In this context, 
the question arose, whether the exchange of cysteine against serine at position 3882 might 
influence the interaction with the complex partners. To answer this question, methylation of 
recombinant H3 by MLL1 wildtype and MLL1 C3882S was conducted in absence or in 
presence of the WRA complex partners. The same experiment was performed with MLL1 
R3841W, MLL1 S3865F and the corresponding C3882S mutants. As described above, MLL1 
was more active in presence of WRA. The same result was obtained with the MLL1 C3882S 
mutant. Also for MLL1 S3865F and MLL1 S3865F/C3882S higher methyltransferase activity 
was observed together with complex partners. In contrast to that, the somatic cancer mutant 
MLL1 R3841W was more active in absence of WRA. No change in the response to the 
presence of complex partners was observed with the MLL1 R3841W/C3882S mutant. These 
findings are in agreement with the previously described results in chapter 4.3.1.1 Figure 13. 
For MLL1, MLL1 R3841W and MLL1 S3865F an increase in automethylation was observed 
in presence of complex partners. Interestingly, automethylation of MLL1 R3841W was 
increased with WRA, but H3 methylation was weaker. This result suggests that WRA 
somehow inhibits the H3 interaction of MLL1 R3841W, which has to be further investigated. 
In summary, the mutation C3882S did not change the enzymatic properties of MLL1 wildtype 
and its somatic cancer mutations in presence or absence of complex partners (Figure 19). 
Figure 19: Automethylation of MLL protein variants and H3 methylation in presence or absence of complex proteins 
WDR5, RBBP5 and ASH2L (WRA). A) 16% SDS gel showing that roughly equal amounts of MLL1 wildtype, MLL1 
C3882S and the complex proteins WDR5, RBBP5 and ASH2L were used for methylation. B) Methylation of H3 by MLL1 
wildtype, MLL R3841W, MLL S3865F and the corresponding C3882S mutants in presence or absence of WRA. Methyl 
transfer was detected by autoradiography. The corresponding bands of the expected size are labeled with asterisk. Exposure 
times are indicated. a= automethylation of MLL1; b= methylation of recombinant H3.
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4.3.1.2.3. Methylation of the non-histone targets by the MLL1 C3882S wildtype and cancer 
 variants 
Using the established C3882S mutants with reduced automethylation, the next aim of this 
study was to investigate if the purified non-histone protein domains are substrates for MLL1 
protein variants and if the substrate preferences differ between wildtype MLL1 and the cancer 
mutants. To ensure almost equal protein amounts in the methylation assay, all selected non-
histone targets were analyzed on SDS gels (Figure 20A). H3 was included as positive control. 
The targets DEGS2 and RADAP were only obtained in low concentrations, which resulted in 
a lower sensitivity in the methylation assay. For methylation, nearly equal amounts of the 
target protein domains were incubated with MLL1 C3882S in the presence of radioactively 
labeled AdoMet. After methylation, samples were loaded on a 16% SDS gel and methylation 
was analyzed by autoradiography. Despite the reduction of automethylation, only methylation 
of the two targets, TICRR and ZNF862, was confirmed, which were already observed before 
(compare Figure 17). Moreover, the data in this experiment showed that automethylation was 
not fully removed as shown after longer exposure times of films (Figure 20B/D).  
As already mentioned, somatic cancer mutations can have different effects on the enzymatic 
properties of PKMTs. Changes in the catalytic properties of MLL1 S3865F and R3841W 
were already shown (4.3.1.1). Now, it was aimed to analyze if any of these MLL1 cancer 
mutations led to changes in the recognition of individual non-histone substrates. In this 
respect, the same methylation reactions of non-histone substrates as just described for MLL1 
wildtype C3882S was performed with MLL1 R3841W/C3882S and MLL1 S3865F/C3882S. 
As shown in Figure 20, MLL1 R3841W and MLL1 S3865F methylate the same non-histone 
targets as MLL1 C3882S. To see if the substrate specificity of the MLL1 protein variants 
changes by the interaction with the complex partners WDR5, RBBP5 and ASH2L, the 
potential non-histone targets were screened with the same MLL1 constructs after complex 
formation with WRA. However, also in presence of WRA, the two non-histone targets, 
TICRR and ZNF862, were methylated by all the MLL1 cancer variants and no additional 
targets were detected (Figure 21). Altogether, these results indicate that the specificity of 
MLL1 protein variants was not changed by the cancer mutations and by the addition of 
complex partners. 
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Figure 20: Screening of the non-histone targets with MLL1 C3882S and its somatic cancer mutants. A) 16% SDS gel of 
MLL1 C3882S with all selected non-histone targets serving as input control for the protein amounts of ACBD6, CCNO, 
TICRR, DEGS2, HAS3, PNMT, RADAP and ZNF862 that were used for methylation. B) Methylation of all proteins by the 
MLL1 C3882S. C) Methylation of all proteins by MLL1 R3841W/C3882S. D) Methylation of all proteins by MLL1 
S3865F/C3882S. Methyl transfer was detected by autoradiography. The corresponding bands of the expected size are labeled 
with asterisk. Exposure times are indicated. a= automethylation of MLL1; b= methylation of recombinant H3.
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Figure 21: Screening of the non-histone targets with MLL1 C3882S and its somatic cancer mutants in presence of WRA. For 
methylation the same protein amounts of ACBD6, CCNO, TICRR, DEGS2, HAS3, PNMT, RADAP and ZNF862 were used 
as shown in Figure 20A. A) Methylation of all proteins by the MLL1 C3882S in presence of WRA. B) Methylation of all 
proteins by MLL1 R3841W/C3882S in presence of WRA. C) Methylation of all proteins by MLL1 S3865F/C3882S in 
presence of WRA. Methyl transfer was detected by autoradiography. The corresponding bands of the expected size are 
labeled with asterisk. Exposure times are indicated. a= methylation of ASH2L; b= automethylation of MLL1; c= methylation 
of recombinant H3.
4.3.1.2.4. Verification of the predicted target lysine residues of TICRR and ZNF862 
An important step in the identification of novel non-histone PKMT substrates is the 
verification that the predicted target lysine of the novel non-histone substrates is indeed the 
place of methylation. For this, the putative target lysine residue was exchanged against an 
arginine by site directed mutagenesis. After successful cloning, the K to R mutants were 
overexpressed and purified by affinity chromatography. Equal amounts of wildtype TICRR or 
ZNF862 and their corresponding target lysine mutants were incubated with MLL1 C3882S 
with or without complex partners. The autoradiography image showed clear loss of the 
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methylation signal for TICRR K1019R and ZNF862 K457R with and without WRA complex 
(Figure 22). This result confirms that both proteins were methylated at their predicted target 
lysine, K1019 in TICRR and K457 in ZNF862. 
Figure 22: Verification of the target lysine methylation of TICRR and ZNF862. A) 16% SDS gel of TICRR and TICRR K to 
R mutant showing that roughly equal protein amounts of both proteins were used for methylation. Methylation of TICRR or 
TICRR KR by the MLL1 WT C3882S in presence or absence of WRA. B) 16% SDS gel of ZNF862 and ZNF862 K to R 
mutant documents that roughly equal protein amounts of both proteins were used for methylation. Methylation of ZNF862 or 
ZNF862 KR by MLL1 WT C3882S in presence or absence of WRA. Methyl transfer was detected by autoradiography. The 
corresponding bands of the expected size are labeled with asterisk. Exposure times are indicated.
4.3.1.2.5. Comparison of methylation activity of MLL1 C3882S cancer variants on H3 and 
 the two novel non-histone targets. 
In the next step, more quantitative methylation experiments with the identified non-histone 
targets were conducted to find out if they are better or worse substrates than H3. As shown 
before, the methylation of H3 with MLL1 C3882S was increased by the addition of complex 
partners. Also, the methylation of TICRR or ZNF862 with MLL1 C3882S was stronger when 
WRA was added. This result indicates that methylation of all substrates by MLL1 C3882S 
was stimulated by WRA, but the stimulatory effect was most pronounced with ZNF862. The 
comparison of the relative activity demonstrates that recombinant H3 was a better substrate 
than TICRR with or without complex proteins for MLL1 C3882S. In contrast, ZNF862 was a 
better substrate than H3 in presence of complex partners (Figure 23/24A). 
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As shown before, methylation of H3 by MLL1 R3841W/C3882S showed higher 
methyltransferase activity alone and addition of complex partners causes a decrease in 
activity. Interestingly, methylation of TICRR and ZNF862 by this mutant was increased after 
addition of WRA. This finding indicates that the methylation of the novel targets was 
stimulated by WRA. Also automethylation of MLL1 R3841W/C3882S was stimulated in the 
presence of complex partners. In contrast, the methylation of H3 by this mutant was reduced 
with WRA. It seems that the interaction of WRA inhibits the binding of H3 to MLL1 
R3841W. The comparison of the relative activities shows that the recombinant H3 was a 
better target than TICRR with or without complex partners, whereas ZNF862 was a better 
substrate than H3 in presence of WRA (Figure 23/24B). 
MLL1 S3865F/C3882S behave similar as the MLL1 C3882S enzyme. The methylation of 
recombinant H3, TICRR and ZNF862 was stimulated by the addition of complex proteins. 
The methylation signal of TICRR in presence of complex partners was comparable to H3 
methylation in absence of WRA. Also for MLL1 S3865F/C3882S, H3 was a better substrate 
than TICRR, with or without WRA. No difference was observed between ZNF862 and H3 in 
presence of complex partners, whereas H3 was a better target than ZNF862 in absence of 
WRA. Altogether, MLL1 C3882S and the MLL1 C3882S cancer variants prefer H3 as target. 
Intriguingly, MLL1 R3841W/C3882S was more active on TICRR and ZNF862 with complex 
partners, whereas on H3 it was more active alone (Figure 23/24C). 
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Figure 23: Comparison of the methylation activity of MLL1 and its somatic cancer mutants on H3 and TICRR. Duplicates of 
each experiment with different film exposition time are presented. A) Methylation of H3 or TICRR by MLL1 C3882S in 
absence (-) or presence (+) of WRA. B) Methylation of H3 or TICRR by MLL1 R3841W/C3882S in absence (-) or presence 
(+) of WRA. D) Methylation of H3 or TICRR by MLL1 S3865F/C3882S in absence (-) or presence (+) of WRA. Methyl 
transfer was detected by autoradiography. The corresponding bands of the expected size are labeled with asterisk. Exposure 
times and methylation of H3 are indicated.
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Figure 24: Comparison of methylation activity of MLL1 and its somatic cancer mutants on H3 and ZNF862. Duplicates of 
each experiment with different film exposition time are presented. A) Methylation of H3 or ZNF862 by MLL1 C3882S in 
absence (-) or presence (+) of WRA. B) Methylation of H3 or ZNF862 by MLL1 R3841W/C3882S in absence (-) or presence 
(+) of WRA. D) Methylation of H3 or ZNF862 by MLL1 S3865F/C3882S in absence (-) or presence (+) of WRA. Methyl 
transfer was detected by autoradiography. The corresponding bands of the expected size are labeled with asterisk. Exposure 
times and methylation of H3 are indicated. 
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4.3.1.2.6. Conclusion and outlook of the experiments with MLL1
Using substrate specificity arrays the recognition of each amino acid in the H3(1-15) peptide 
sequence by MLL1 was analyzed in detail. With the identified substrate recognition motif, 98 
potential non-histone substrates were identified. Out of these, 23 targets were methylated by 
MLL1 at the peptide level. To test the methylation at the protein level, 8 non-histone targets 
could be successfully overexpressed and purified. Out of 8 potential new protein substrates 
tested, two were methylated at the predicted target lysine residue by MLL1 variants in 
presence or absence of WRA. Unfortunately, MLL1 showed strong automethylation, which 
reduced the sensitivity of the methylation assay with non-histone targets in the first attempt. 
By mutation of cysteine to serine at position 3882, automethylation of MLL1 and its mutants 
was strongly reduced. Only in the case of R3864C, automethylation could not be removed, 
because the newly introduced cysteine at position 3864 also was methylated. It was confirmed 
that the C3882S mutation does not change the enzymatic properties of MLL1, MLL1 
R3841W or MLL1 S3865F. Out of 8 proteins tested, two non-histone targets were methylated 
at the predicted target lysine residue by MLL1 variants in presence or absence of WRA. 
However, the removal of automethylation did not reveal any additional methylation targets. In 
absence of complex proteins, all MLL1 variants prefer H3 as substrate. With complex 
partners, all MLL1 variants showed stronger methylation activity on ZNF862 than on H3. 
In future experiments, it would be necessary to analyze, if the strong methylation activity on 
ZNF862 is due to stronger binding to MLL1. This could be performed by pull-down 
experiments. Furthermore, it would be interesting to determine the methylation degree of the 
identified non-histone targets. Finally, cellular studies with TICRR and ZNF862 would give 
further insights into the potential biological functions of these methylation events. 
4.3.2. Investigation of the MLL3 protein lysine methyltransferase 
4.3.2.1. Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties 
 of the enzyme 
(Manuscript 4 in the attachment of this thesis) 
Weirich S, Kudithipudi S, Kycia I & Jeltsch A. (2015). Clinical Epigenetics, 2015 Mar 
28;7:36. doi: 10.1186/s13148-015-0075-3.  
The MLL3 (KMT2C) protein is another member of the MLL protein family. It is a 4911 
amino acids long enzyme (Smith et al. 2011) that functions mainly as a 
monomethyltransferase introducing H3K4me1 at active enhancers (Cheng et al. 2014). MLL3 
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has been found mutated in several cancers including glioblastoma, melanoma, pancreatic and 
breast cancer (Chen et al. 2014; Kandoth et al. 2013; Kudithipudi & Jeltsch 2014) and recent 
studies reported that MLL3 is one of the most frequently mutated protein lysine 
methyltransferase in cancer (Chen et al. 2014; Kandoth et al. 2013; Kudithipudi & Jeltsch 
2014). Using the COSMIC database, three missense mutations located in the catalytic SET 
domain of MLL3 (4771 to 4911) were selected for biochemical analysis based on their 
location either close to the peptide or AdoMet binding sites of the enzyme: S4757C (found in 
lung cancer), N4848S (found in endometrium, central nervous system) and Y4884C (found in 
large intestine) (manuscript 4, Figure 1). MLL3 wildtype and the selected cancer mutants 
were cloned as GST-fusion proteins and purified via affinity chromatography (manuscript 4, 
Suppl. Figure 1A). Methylation experiments indicated that MLL3 wildtype is strongly 
stimulated by the presence of the WRA complex proteins. The two mutants, S4757C and 
Y4884C, behave similar to MLL3 wildtype by showing an increased catalytic activity in the 
presence of complex partners. However, the activity of Y4884C was 4-fold reduced by WRA. 
The amino acid exchange from asparagine to serine at position 4848 converts MLL3 to an 
inactive methyltransferase (Figure 25). Correct protein folding of all proteins was confirmed 
by analyzing the secondary structure composition with CD spectroscopy (manuscript 4, 
Suppl. Figure 1B).  
Figure 25: Activity of MLL3 protein variants. Recombinant histone H3 protein was methylated with radioactively labeled 
AdoMet by MLL3-SET wildtype and MLL3-SET mutant proteins either alone or in the presence of complex member 
proteins. A) Example of an autoradiographic image of the SDS polyacrylamide gel. The methylation signal of H3 is 
indicated. B) Quantitative analysis of the averages of duplicate experiments. The error bars indicate the standard error of the 
mean. (Taken from manuscript 4, Figure 2) 
57
To further analyze the effects of these mutations on the substrate specificity and product 
pattern, peptide methylation experiment were carried out. SPOT peptide arrays with different 
methylated forms of H3K4 and a K4A mutant peptide as negative control were incubated with 
the MLL3 variants in presence of complex partners and radioactively labeled AdoMet. In 
agreement with the previous result, N4848S mutant was inactive. MLL3 wildtype and 
S4757C preferred the unmethylated H3K4 peptide as substrate, and no methylation was 
observed with methylated H3K4 peptides. However, a strong change in the substrate 
specificity for Y4884C was observed. The Y4884C variant preferred the H3K4me1 peptide as 
substrate and additionally weak methylation was observed with H3K4me2 substrate. These 
results show that MLL3 and S4757C transfer one single methyl group on unmethylated 
H3K4, whereas Y4884C can transfer up to three methyl groups and it prefers H3K4me1 as 
substrate (Figure 26A). Mass spectroscopy measurements were used to further analyze the 
change in the substrate and product specificity of Y4884C variant. MLL3 wildtype and 
Y4884C variant were incubated in presence of complex partners with soluble unmethylated or 
monomethylated H3 peptides and the methylation reaction was analyzed at different time 
points. MLL3 wildtype was shown to be a strict monomethyltransferase only using 
unmethylated H3K4 peptide as substrate (Hu et al. 2013; Herz et al. 2012). The same results 
were obtained using the S4757C mutant. Interestingly, Y4884C was only weakly active on 
H3K4me0 peptide. Still, no accumulation of H3K4me1 appeared which implies that this 
mutated enzyme immediately converts monomethylated H3K4 peptide into the di- and 
trimethylated forms. Using monomethylated H3K4 peptide substrate, strong methylation 
signals were observed and the dimethylated and trimethylated H3K4 peptide products were 
generated (manuscript 4, Figure 4). 
Change in the product specificity of MLL3 Y4884C was also observed at the protein level 
using recombinant histone H3 as substrate. After the methylation reactions, the samples were 
separated via SDS-PAGE and H3K4 trimethylation was detected using an H3K4me3 
antibody. In presence of complex partners, a strong H3K4 trimethylation signal was detected 
after H3 methylation with the Y4884C mutant, whereas with MLL3 wildtype only a weak 
signal was observed. Without complex partners both enzymes did not show activity (Figure 
26B). Furthermore, the global H3K4me3 level was analyzed in cells after overexpression of 
the different cancer mutants. Therefore, histones were isolated from HEK293 cells, which 
were transfected with expression constructs of the individual MLL3 cancer variants. The 
histones were separated via SDS-PAGE and methylation analyzed with H3K4me3 antibody. 
Similarly as in the in vitro reaction, transiently expressed Y4884C increased the H3K4me3 
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signal (Figure 26C), while the other mutants did not show clear differences to the wildtype 
result. In summary, this research shows that somatic cancer mutations can have individual and 
specific effects on the enzymatic properties of PKMTs. In the case of MLL3, the mutation 
N4848S converts MLL3 to an inactive enzyme, whereas S4757C shows no significant 
changes compared to MLL3 wildtype. Still, there can be differences, which were not detected 
with these experimental approaches. Interestingly, exchange of tyrosine to cysteine at position 
4884 results in the conversion of MLL3 from a monomethyltransferase to a 
trimethyltransferase, which was confirmed in vitro and in cells. This observation is in analogy 
to EZH2 Y641 as described in chapter 1.10. 
Figure 26: Substrate and product specificity of MLL3 protein variants. A) H3(1-15) peptide arrays containing H3K4 at 
different methylation states and a K4A variant peptide were methylated with MLL3-SET wildtype and mutant proteins in the 
presence of complex members using radioactively labeled AdoMet. The figures show an example of an autoradiographic 
image of the methylated peptide SPOT arrays, peptides with the corresponding lysine variants are indicated (Taken from 
manuscript 4 Figure 3A). B) Methylation of recombinant histone H3 protein by MLL3-SET wildtype and Y4884C alone and 
in the presence of complex members using unlabeled AdoMet as cofactor. After methylation the proteins were separated on a 
SDS polyacrylamide gel, blotted and the methylation was detected using an H3K4 trimethylated antibody (upper panel). The 
lower panel shows the Ponceau S stained image of the blot (Taken from manuscript 4 Figure 6A). C) Global histone 
H3K4me3 methylation analysis from HEK293 cells. The cells were transfected with different MLL3 variant plasmids, 
histones were isolated and H3K4me3 methylation probed by western blot. The upper image shows the H3K4me3 signal and a 
Ponceau S stain as loading control. The bar diagram shows the quantification from 3 experiments. The error bars display the 
standard error of the mean. The signal obtained from the MLL3 was set to 1 and the other signals were normalized 
accordingly (Taken from manuscript 4 Figure 6B). 
4.3.2.2. Specificity analysis of MLL3 in complex with WDR5, RBBP5 and ASH2L 
As it was already described for MLL1 in 4.3.1.2.1, a peptide array was used to investigate the 
influence of each amino acid in the H3(1-15) template for the substrate recognition by MLL3. 
In the case of MLL3, methylation of the substrate specificity array was performed in presence 
of complex partners WDR5, RBBP5 and ASH2L, as MLL3 was only active in presence of 
complex partners (4.3.2.1). After methylation of the peptide array with the MLL3-WRA 
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protein complex in the presence of radioactively labeled AdoMet, the methyl transfer was 
analyzed by autoradiography. The experiment was carried out twice and the average activities 
were calculated and plotted in Figure 27A. The calculation of the standard deviation for the 
methylation activity of each peptide from both experiments showed that the results are highly 
reproducible with a SD smaller than 20% for 92.5% of the peptides. 99% of the peptides have 
a SD < 30% and only 2 peptides showed a SD between 30 and 40% (Figure 27B). 
The results show that MLL3-WRA recognizes the template H3 (1-15) residues from A1 to 
T6. At position -2, MLL3-WRA mainly tolerates the canonical arginine and only weakly 
accepts leucine. Alanine at position -3 can be replaced by all other hydrophobic residues, 
additionally serine and threonine were accepted. Beside glutamine at position +1, MLL3-
WRA has also a good activity with asparagine, histidine and methionine. In summary, the 
substrate specificity recognition motif can be described as follows: 
A(ILFP)-R(L)-T(AILMFYV)-K-Q(NHM)-T(AQEILSV).  
Figure 27: Substrate specificity analysis of MLL3 in complex with WRA. A) Two independent peptide array methylation 
experiments were performed with MLL3+WRA and the data were averaged after normalizing the full activity to 1. The 
activity is displayed in the grey scale as indicated. The horizontal axis represents the template sequence (H3 1-15). Each 
residue was exchanged against all 20 natural amino acid residues as indicated by the vertical axis. B) Distribution of standard 
errors of the mean of MLL3+WRA on all peptides tested in the two independent assays. 
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To screen the human proteome for possible non-histone targets of MLL3, a Scansite search 
with the substrate recognition motif was conducted and 42 potential non-histone substrates 
were identified (Obenauer et al. 2003). To check if the identified non-histone targets can be 
methylated at peptide level, 15 amino acid long peptides were synthesized on a cellulose 
membrane. The peptide array was incubated with MLL3 complex containing WDR5, RBBP5 
and ASH2L in presence of radioactively labeled AdoMet and the methyl group transfer was 
detected by autoradiography. Out of the 42 putative non-histone targets (Table 5, see 
appendix), 24 were methylated (Figure 28A). Out of these, 10 target protein domains were 
selected (Table 2), overexpressed and purified by affinity chromatography (Figure 28B). 
Figure 28: Screening of MLL3 non-histone targets. A) The peptide array was methylated with MLL3 together with WRA in 
presence of radioactively labeled AdoMet. The transfer of the methyl group to the immobilized target lysine residues was 
detected by autoradiography. Target information is listed in Table 5. B) 16% SDS gel documents the purification of 10 non-
histone targets. The corresponding bands of the expected size are labeled with asterisk. 
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Table 2: Selected non-histone targets from the peptide array (Figure 28A), which were further analyzed. 
Swiss 
Prot. Nr. 
Original name Name Sequence 
Protein-
length 
MW 
(kDa) 
Target 
K 
position
A6 Q8WYP5 ELYS_HUMAN  Protein ELYS DKQLRIKHVRRVRGR 2266 253 1933 
A13 P78412 IRX6_HUMAN  
Iroquois-class 
homeodomain protein 
IRX-6 
SGAGRRKNATRETTS 446 48 151 
A16 Q7L590 MCM10_HUMAN Protein MCM10 homolog PALPRTKRVARTPKA 875 98 187 
A19 Q8IYA7 MKX_HUMAN  
Homeobox protein 
Mohawk 
NARRRLKNTVRQPDL 352 39 129 
B9 Q8N488 RYBP_HUMAN 
RING1 and YY1-binding 
protein 
TSRPRLKNVDRSTAQ 228 25 149 
B11 P42229 STA5A_HUMAN  
Signal transducer and 
activator of transcription 
5A / 5B 
MSLKRIKRADRRGAE 794 91 425 
B17 Q8IY57 YAF2_HUMAN YY1-associated factor 2 KTRPRLKNVDRSSAQ 180 20 106 
B19 Q86UD4 ZN329_HUMAN Zinc finger protein 329 MRLKMTTRNFPEREV 541 62 4 
B20 O60290 ZN862_HUMAN  Zinc finger protein 862 DGPRRIKRTYRPRSI 1169 132 457 
C2 Q8IYH5 ZZZ3_HUMAN  
ZZ-type zinc finger-
containing protein 3 
PVLKRIKRCLRSEAP 903 102 117/120 
Equal amounts of RYBP, YAF2, MKX and ZN329 (Figure 29A) were incubated with the 
MLL3-WRA complex (Figure 29B) in a reaction mixture containing radioactively labeled 
AdoMet, to investigate methylation of the candidate substrate proteins. As positive control, 
H3 was included. To rule out any methylation signal from the MLL3 or its complex partners, 
MLL3-WRA was also incubated under the same conditions without any substrate. Strong 
methylation of the recombinant H3 was detected. In addition, methylation of ASH2L was 
observed. Further investigation is necessary to analyze if MLL1 catalyze the methylation of 
ASH2L or if ASH2L automethylation is observed. However, even after long exposure, none 
of the four selected non-histone targets was methylated by MLL3 in presence of complex 
partners (Figure 29C). 
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Figure 29: Methylation of non-histone proteins by MLL3. A) 16% SDS gel of all selected non-histone targets serving as 
input control of the protein amounts of RYBP, YAF2, MKX and ZN329 that were used for methylation. B) 16% SDS gel of 
MLL3 with the complex proteins WDR5, RBBP5 and ASH2L showing that roughly equal protein amounts of all proteins 
were used for methylation C) Methylation of RYBP, YAF2, MKX and ZN329 by MLL3 in presence of WRA. Methyl 
transfer was detected by autoradiography. The corresponding bands of the expected size are labeled with asterisk. Exposure 
times are indicated. a= methylation of ASH2L; b= automethylation of MLL3; c= methylation of recombinant H3.  
4.3.2.2.1. Conclusion and outlook of the MLL3 experiments 
MLL3 substrate specificity peptide arrays were used to analyze the interaction of MLL3 
complex with the amino acids of the H3 peptide (1-15). Using a Scansite search, 42 potential 
non-histone targets with the identified substrate recognition motif were found. Out of these, 
24 peptides were methylated and 10 corresponding proteins were successfully overexpressed 
and purified. Methylation was performed for RYBP, YAF2, MKX and ZN329 with MLL3 in 
complex, but no methylation of any of the non-histone substrates could be identified. More 
research is necessary to test the potential methylation of the other non-histone protein 
domains (IRX, MCM, ZN862, ZZZ3, ELYS and STRA5A). In addition, more targets can be 
selected on the peptide array to test methylation at protein level. Furthermore, methylation of 
the targets should be performed with MLL3 in absence of complex partners, because it is 
possible that WRA influences the specificity of MLL3. 
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5. Discussion 
Histone lysine methylation is an abundant posttranslational modification with very important 
roles in the regulation of epigenetic mechanisms. Different protein lysine methyltransferases 
are known to catalyze mono-, di- and trimethylation of lysine residues. Dependent on the 
methylation degree and the methylated residue, lysine methylation is associated with 
transcriptional activity, repression or other functions. Since the discovery of the first protein 
lysine methyltransferase Suv39h1 by Jenuwein (Rea et al. 2000), the insight into the 
biological relevance of protein lysine methylation has increased drastically. Many PKMTs 
were identified and it was shown that different enzymes methylate the same target site, but 
sometimes also different target sites are methylated by the same PKMT. In addition, non-
histone proteins were identified as possible substrates for methyltransferases. By now, several 
hundreds of methylated target lysine residues in the human proteome have been detected, but 
the responsible PKMTs are not yet identified. On the other hand, for many PKMTs the variety 
of relevant targets is unknown. However, due to the fast development of the field wrong 
assignments occurred between PKMTs and methylated target sites, which led to wrong 
interpretation of biological processes. 
In this study, the substrate specificity of SUV4-20H1, SUV4-20H2, MLL1 and MLL3 was 
determined and it was demonstrated that specificity analysis is a powerful strategy to identify 
novel non-histone targets for PKMTs and to prevent mis-assignment. In addition, detailed 
biochemical investigations of the effects of somatic cancer mutations in PKMTs showed 
mutation related changes of the enzymatic properties. This discovery suggests the 
development of cancer specific therapeutic strategies. 
The following chapters represent a summarized discussion of all projects. A more detailed 
discussion of individual results is presented in the different publications attached in the 
appendix. 
5.1. Substrate and product specificity of SUV4-20H1 and SUV4-20H2 
In mammals, many chromatin modifying enzymes are present in two or more paralogs, like 
MLL1/2, MLL3/4, and G9A/GLP. All of them have overlapping, but also non-redundant 
biological functions. In this study, the two paralogs SUV4-20H1 and SUV4-20H2 were 
further investigated. In human cells, three enzymes SET8, SUV4-20H1 and SUV4-20H2 are 
the most important H4K20 methyltransferases. SET8 is known as a strict H4K20 
monomethyltransferase (Zhang & Bruice 2008). In contrast, previous studies raised questions 
regarding the product and substrate specificity of the two paralogs SUV4-20H1 and SUV4-
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20H2. Southall et al. (2014) reported a ~ 10 fold preference, whereas Wu et al. (2013) 
observed a ~ 3 fold preference of SUV4-20H enzymes for monomethylated H4K20 substrate 
over unmethylated ones. Even though both groups showed different preferences, they 
reported that SUV4-20H enzymes transfer one single methyl group on H4K20me1. However, 
H4K20 trimethylation was detected with an antibody even in an in vitro reaction, when 
recombinant nucleosomes were used as substrates (Schotta et al. 2004). 
5.1.1. The methylation pattern of SUV4-20H1 and SUV4-20H2 
In this study, peptide array methylation experiments and methylation of purified peptides in 
solution have shown very similar substrate and product methylation state preferences for both 
SUV4-20H enzymes. Both enzymes prefer monomethylated H4K20 as substrate to catalyze 
higher methylation forms. These findings were underscored by knock-out studies of SET8 
that led to global losses of H4K20me1, but also H4K20me2 and H4K20me3 (Oda et al. 2009; 
Wu et al. 2013; Southall et al. 2014). Moreover, different lines of evidence indicated in this 
work that SUV4-20H enzymes transfer one methyl group on monomethylated target substrate 
in vitro. This result is also in agreement with other studies and can be explained by the unique 
active site geometry of SUV4-20H1 and SUV4-20H2. In canonical monomethyltransferases 
(e.g. SET8), a tyrosine residue is located in the SET domain and interacts with the ε-amino 
group of the target lysine. Compared to that, SUV4-20H enzymes contain a serine residue 
which enlarges the pocket and allow binding of monomethylated substrates. Similarly as the 
tyrosine in SET8, the serine forms a hydrogen bond with the Nε of the target lysine and this 
interaction prevents rotation of the lysine residue and limits the enzyme to the transfer of only 
one methyl group on the monomethylated H4K20 substrate (Southall et al. 2014; Wu et al. 
2013). This result is not compatible with knock-out studies of SUV4-20H enzymes, which led 
to a genome wide loss of H4K20me2 and –me3 in mice and zebrafish (Schotta et al. 2004; 
Kuo et al. 2012). As mentioned above, H4K20 trimethylation was also observed when 
nucleosomes were used as substrates (Schotta et al. 2004), which may explain this 
discrepancy. Alternatively (but less likely) another enzyme may use dimethylated H4K20 as 
substrate to introduce H4K20me3 in vivo or the product pattern of SUV4-20H enzymes is 
different in cells. Altogether, it was shown that both paralogs have similar properties 
regarding the methylation state preference and the number of transferred methyl groups. 
5.1.2. The substrate specificity of SUV4-20H1 and SUV4-20H2 
Substrate specificity analysis was performed to analyze the influence of each single amino 
acid in the histone template sequence on the enzymatic activity and identify possible 
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differences between the substrate peptide interaction of SUV4-20H1 and SUV4-20H2. 
Interestingly, the data indicated that SUV4-20H1 and SUV4-20H2 recognize (RY)-Kme1-
(IVLM)-(LFI)-X-D and X-Kme1-(IVLMK)-(LVFI)-X-(DEV) sequences. Hence, both 
enzymes have overlapping sequence recognition motifs, but at two positions SUV4-20H1 is 
more specific towards H4K20 than SUV4-20H2. Especially at position -1, SUV4-20H1 only 
tolerates an arginine, whereas SUV4-20H2 accepts several other residues. Similarly, at 
position +4 SUV4-20H1 is only active when aspartic acid is present, but in the case of SUV4-
20H2 aspartic acid at position +4 can be exchanged by glutamic acid or asparagine. This 
difference in the recognition motifs indicates that SUV4-20H2 is less specific than SUV4-
20H1 and suggest that SUV4-20H2 can methylate more non-histone targets than SUV4-20H1.
5.1.3. Identification of NHT for SUV4-20H1 and SUV4-20H2 
The identified sequence recognition motif of SUV4-20H2 was used to search for potential 
non-histone substrates, because it also covers the recognition motif of SUV4-20H1. The 
Phosphosite PLUS database has listed all human proteins, which have been found to be 
methylated in proteomic experiments, but often the responsible PKMT is not yet identified 
(Hornbeck et al. 2015). A search in Phosphosite PLUS revealed seven non-histone proteins 
that are lysine methylated within the sequence recognition motif of SUV4-20H enzymes. 
SUV4-20H2 methylates three (CASZ1, OIP5 and CENPU) out of the 7 potential NHT. In 
comparison to that, SUV4-20H1 methylates only one target (CASZ1), which is in agreement 
with the observation that it is more specific. Interestingly, among all 7 proteins only CASZ1 
carries an R at position -1, a finding that underscores the importance of R at position -1 for 
SUV4-20H1. The two non-histone substrates OIP5 and CENPU, which are methylated by 
SUV4-20H2, are both centromeric proteins, suggesting that they may have a role in 
heterochromatin organization and may come in contact with SUV4-20H2 in cells. CASZ1 is a 
zinc finger transcription factor and may support SUV4-20H1 and H2 in gene regulation. 
Overall, these data indicate that substrate recognition analysis is a promising strategy to 
identify even subtle differences in properties of PKMT paralogs. This information can help to 
get further insights into their individual biological roles. 
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5.2. Investigation of problematic assignments between PKMTs and 
 methylated target sites 
5.2.1. Investigation of the methylation of ERK1 by SUV4-20H1 
Recently, it was reported that ERK1 is methylated by SUV4-20H1 at K302 and K361 
(Vougiouklakis et al. 2015). However, a comparison with the identified specificity profile of 
SUV4-20H1 has shown that the surrounding sequences of both reported target lysine residues 
are not fitting to the requirements of SUV4-20H1. In addition, it was reported that SUV4-
20H1 introduces a trimethylation on the unmethylated ERK1 target substrate, which is in 
disagreement with results presented above regarding the substrate methylation state 
preferences of SUV4-20H1. To solve this discrepancy, further methylation experiments were 
performed in this study. However methylation experiments with ERK1 peptides and protein 
did not provide any evidence for methylation of ERK1 by SUV4-20H1 or SUV4-20H2. 
While working on ERK1 methylation, additional weaknesses of the Vougiouklakis et al. 
(2015) study were recognized. When searching for novel non-histone targets, it is important 
to include known targets as positive controls to compare the relative activity. Vougiouklakis 
et al. (2015) performed methylation of ERK1 with recombinant SUV4-20H1 using 
radioactively labeled AdoMet, but no positive control was included and also no quantification 
was done. Thus, no statement can be made about the strength of the methylation signal on 
ERK1. By MS/MS measurements, they identified K302 and K361 as target lysine sites for the 
methylation by SUV4-20H1. However, surprisingly individual mutations of single target 
residues to alanine completely abolished ERK1 methylation, although the second lysine 
residue was still present. Moreover, when searching for new PKMT substrates, it is helpful to 
use inactive enzyme variants to check if detected methylation events are really catalyzed by 
the enzyme of interest or if methylation signals are coming from contaminating PKMT 
activity copurified with the enzyme. This speculation appeared, because Vougiouklakis et al. 
(2015) did not show the purified protein and also the source and purification method were not 
described. In addition, the reported methylation of ERK1 by SUV4-20H1 was very weak, as 
judged by the images provided by the authors. Weak methylation signals can occur from 
binding of AdoMet to the protein or non-specific methylation detected after long exposure. 
This possibility can be excluded if parallel reactions are conducted with an inactive enzyme 
variant as well as positive controls are included. One potential problem in my study was that 
mouse SUV4-20H enzymes were used to methylate human ERK1 protein, which could be the 
reason for the missing ERK1 methylation. However, sequence comparison of human and 
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mouse SUV4-20H1/H2 as well as human and mouse ERK1 ruled out across species 
discrepancies. Human and mouse SUV4-20H1 differ only at two residues, which are located 
far away from the peptide binding site. No difference was observed within the peptide 
recognition motif of SUV4-20H enzymes between human and mouse ERK1. In summary, if 
true, methylation of ERK1 by SUV4-20H1 would be a very relevant finding, because ERK1 
activity plays a central role in carcinogenesis and a potential role of SUV4-20H1 in this 
process would be very important. One may speculate that substrate and product methylation 
state preferences may change with different substrates, but there is no precedence case for this 
speculation. Therefore it is not possible to completely rule out the methylation of ERK1 by 
SUV4-20H1, based on the data presented here, but one need to take the claim of ERK1 
methylation by SUV4-20H1 with a lot of care, and additional supportive evidence would be 
needed before follow up studies on biological roles of this methylation event are 
recommended. 
5.2.2. Investigation of the methylation of Numb by SET8 
The methylation of the Numb protein by the SET8 protein lysine methyltransferase, is another 
example for a problematic assignment between methylation site and PKMT (Dhami et al. 
2013). Numb was shown to have a tumor-suppressive function acting in a p53 dependent 
manner. Dhami et al. (2013) reported that the interaction between p53 and Numb is regulated 
by the methyltransferase SET8. They reported that SET8 dimethylates Numb at K158 and 
K163. Methylated Numb was found to disrupt the interaction with p53, which then is 
ubiquitinated and finally degraded. However, also in this case, the surrounding sequences of 
the predicted target lysine residues differ from the specificity profile of SET8 at 4 out of 6 
positions. Additionally, SET8 is a strict monomethyltransferase and dimethylation was not 
reported before. In this study, a further investigation of Numb methylation by SET8 revealed 
that this enzyme is not able to methylate Numb at K158 or K163 in vitro. Similarly as 
described in the previous example, Dhami et al. (2013) also missed to include essential 
controls in their study. For methylation experiments, SET8 protein was used that was purified 
from cells by immunoprecipitation. The purity of the sample was not shown and no 
catalytically inactive SET8 enzyme was included to confirm the purity of the 
immunoprecipitated enzyme. Therefore, it cannot be excluded that the reported methylation 
signal comes from another PKMT co-immunoprecipitated with SET8. Furthermore, positive 
controls were missing as well, which would have allowed to relate the methylation activity at 
novel sites to that at already known and well characterized sites. In my study, H4 and p53 
proteins were included as positive controls, because previous studies indicate methylation of 
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these two proteins by SET8 (Shi et al. 2007; Zhang & Bruice 2008). Both substrates were 
methylated, showing that SET8 was active and the methylation assay was sensitive. Although 
Numb methylation could not be detected in vitro, in vivo methylation cannot be completely 
ruled out, because interaction partners or posttranslational modifications can influence the 
substrate preference of PKMTs. However, up to date changes in the substrate specificity due 
to interaction partners or PTMs were only shown for PKMTs, which are not very specific 
regarding the peptide sequence (like SET7/9 (Dhayalan et al. 2011) or PRMTs (Herrmann et 
al. 2009)). Since SET8 is highly specific towards H4K20, changes in its substrate specificity 
are not expected. After including all mentioned controls, it appears more likely that Numb is 
methylated by another not yet identified PKMT. 
More examples exist in which the substrate preference was used to identify wrong assignment 
of methylation substrates to PKMTs. NSD1 was reported to methylate H3K36, H4K20 and 
the p65 non-histone target (Berdasco et al. 2009; Lu et al. 2010; Rayasam et al. 2003). 
Kudithipudi et al. (2014) identified the substrate recognition motif 
(YFG)(VLI)K(QRKNM)(IVP) that differs from the surrounding residues of H4K20 and p65 
(Kudithipudi, Lungu, et al. 2014) . Indeed, absence of H4K20 and p65 methylation was 
confirmed, whereas methylation of H4K44 was detected. The sequence context of H4K44 
matches with the sequence preference of NSD1. Sone et al. (2014) described that SUV39H2 
catalyze methylation of H2AX at lysine 134 (Sone et al. 2014). It was shown that H2AX 
methylation imply enhanced phosphorylation of serine at position 139, which led to increased 
activation of DNA damage repair pathway. Again, a mismatch between the H2AX sequence 
and SUV39H2 sequence preference revealed a wrong assignment between PKMT and 
methylated target site (Schuhmacher et al. 2016). Altogether, these findings demonstrate that 
substrate specificity analyses are important to characterize PKMTs, because they are very 
predictive in the validation of previously reported PKMT substrates and can guide the 
discovery of novel PKMT substrates. 
5.3. Substrate specificity analysis of MLL family PKMTs 
The MLL PKMT family consists of six enzymes, MLL1/2, MLL3/4 and SET1A/B, all 
catalyzing H3K4 methylation that is associated with actively transcribed genes. Each pair of 
human paralogs corresponds to one of the three H3K4 methyltransferases Drosophila 
melanogaster, namely SET domain-containing 1 (Set1), Trithorax (Trx) and Trithorax-related 
(Trr) (Piunti & Shilatifard 2016). The human paralogs are characterized by a high sequence 
similarity and similar domain organization, which led to their classification (Smith et al. 
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2011). MLL proteins are found in multi protein complexes in eukaryotic cells. The WRA 
complex is common for all MLL proteins and is responsible for the stimulation of the 
methyltransferase activity of the enzyme. DPY30 is also a common member of all MLL 
complexes, but is not an essential complex partner for the stimulatory effect of the 
methyltransferase activity (Patel et al. 2009). In addition, each MLL subfamily has specific 
additional complex partners related to their individual biological roles (Smith et al. 2011). 
The three subfamilies introduce different methylation states on H3K4 at specific target gene 
loci as described in 1.12. 
As described above, in the past many PKMTs were found to methylate non-histone proteins 
as well. In this study, MLL1 and MLL3 were selected to be further characterized in this 
respect. The substrate specificity profile was used for the identification of potential PKMT 
substrates in proteome wide searches. In addition, somatic cancer mutations were found in 
PKMTs, which have a central role in carcinogenesis. In previous studies it was shown that 
somatic cancer mutations have several effects that influence the properties of an enzyme, like 
activity, product and substrate specificity. Here, the effect of somatic cancer mutations on the 
properties of MLL1 and MLL3 were investigated. 
5.3.1. Substrate specificity analysis of MLL1 
In the present study a substrate specificity analysis was performed for MLL1. One aim of this 
analysis was the identification of novel non-histone targets of this enzyme. Moreover, the 
analysis allowed to investigate if WRA complex formation influences the substrate 
recognition and to study the potential effect of somatic cancer mutations in this enzyme on its 
specificity. With peptide array methylation experiments it was shown that MLL1 specifically 
discriminates residues of the H3 sequence from A1 to R8. Especially at position -2 and +4 
high specificity was identified. Exchange of the canonical arginine by any other amino acid at 
position -2 completely abolished the methyltransferase activity of MLL1. At position +4, 
MLL1 also prefers arginine, but weakly accepts cysteine or tyrosine. The crystal structure of 
MLL1 reveals that R8 forms a water mediated hydrogen bond with serine 3915, which may 
explain the sequence recognition of this residue (Southall et al. 2009). Using the identified 
recognition motif, 98 putative non-histone targets were found with the Scansite database and 
methylation by MLL1 was investigated at the peptide level. Out of the 98 non-histone 
peptides, 23 targets were methylated. Especially two peptide targets, TICRR and ZNF862, 
indicated strong methylation signal. 15 of these 23 peptide substrates were selected for protein 
methylation analysis, 8 of them were successfully cloned, overexpressed and purified. 
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Unfortunately, while screening the purified non-histone protein methylation, a strong 
automethylation of MLL1 was observed that overlapped with the potential substrate 
methylation signal. Still, methylation signals were observed for two proteins, TICRR and 
ZNF862, corresponding to the strongly methylated peptides mentioned above. Both targets 
contain an arginine residue at position -2. At position +4, only ZNF862 has the preferred 
arginine, whereas TICRR has a phenylalanine. Hence, stronger methylation of ZNF862 
compared to TICRR illustrates the accuracy of the substrate specificity profile analysis. 
In future cellular methylation of these proteins should be investigated and the methylation 
degree of TICRR and ZNF862 has to be analyzed by MALDI measurements of samples 
methylated in vitro and in vivo. The methylation of the additional 98 non-histone peptide 
targets should also be analyzed in presence of complex partners, to see if different targets are 
methylated. 
5.4. Screening of NHT methylation by the MLL1 wildtype 
To further analyze methylation of non-histone proteins by MLL1, the automethylation signal 
of MLL1 had to be removed or at least reduced. Patel et al. (2014) reported that the 
automethylation occurs at cysteine 3882, which is located in the SET-I subdomain of the SET 
domain (Patel et al. 2014). The SET-I region in MLL proteins is differently oriented than in 
other SET domain containing proteins, because it exists in open conformation where the 
target lysine cannot be properly oriented for optimal methyl transfer. Cysteine 3882 belongs 
to the channel tetrapeptide from Cys3882 to Phe3885 that forms one side of the substrate 
lysine alkyl binding channel, which is shifted away from the SET-C region in the open 
conformation (Southall et al. 2009). Interestingly, the distance between this cysteine and the 
AdoMet methyl group is about 10 Å in the open conformation, indicating that the SET-I 
region must close down during turnover. It was shown that binding of unmodified H3 reduces 
the automethylation signal,because the substrate bound in the active site pocket prevents an 
approach of the Cys to the AdoMet. This is in agreement with the results reported in the 
present thesis. Patel and colleagues reported that an exchange of cysteine 3882 against serine 
removed most of the automethylation, but it was not diminished completely. 
In this study, the automethylation was successfully reduced for MLL1 wildtype by 
introduction of the C3882S mutation. However, the H3 methylation of the MLL1 C3882S 
protein was weaker compared to the methylation with the MLL1 wildtype protein. As already 
mentioned, cysteine 3882 is located in the SET-I lobe within the catalytically active pocket. It 
is possible that the exchange of cysteine against serine shifts the conformation into the 
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inactive state, for example, serine is more hydrophilic than cysteine, which may induce an 
opening of the structure. In presence of complex partners, the methyltransferase activity of 
MLL1 is getting stimulated. Therefore, in the next step it was investigated if the C3882S 
mutation influences the enzymatic properties of the MLL1 protein in presence of complex 
partners. It was shown that the exchange of cysteine against serine did not change the 
interaction with the complex partners. Interestingly, the methylation signals of H3 were 
comparable between MLL1 C3882S variants and the MLL1 wildtype protein in presence of 
WRA, whereas reduced methylation activity was observed for the MLL1 C3882S variant in 
absence of complex partners as mentioned above. This result additionally supports the 
suggestion that the C3882S mutation pushes the conformation of the SET-I helix more into 
the inactive state in absence of complex partners. Apparently, the binding of WRA can 
overcome this effect. Furthermore, in presence of WRA an increased automethylation signal 
was detected for the MLL1 protein. This finding is in agreement with the model that WRA 
stabilize the SET-I helix in the closed conformation and thereby diminishes the distance 
between C3882 and AdoMet, which is the reason for stronger automethylation.  
After successful reduction of the automethylation signal for MLL1, the C3882S mutant was 
used to investigate the methylation of the selected non-histone proteins in presence or in 
absence of complex partners. The MLL1 protein with or without WRA methylated the two 
targets, TICRR and ZNF862, which were already observed before. 
Methylation of the target lysine residues of both proteins was verified by mutation of TICRR 
K1017 and ZNF862 K457 to Arg, both resulting in a complete loss of target methylation. 
Next, a direct comparison of the efficiency of MLL1 methylation was performed between the 
known H3 target and the two novel identified substrates. In the absence of complex partners, 
H3 was the best target, but in presence of complex partners, ZNF862 was stronger methylated 
than H3. This means methylation of ZNF862 must be tested in cells and it could be 
physiologically very relevant. 
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5.5. Screening of NHT methylation by the somatic cancer mutants of 
 MLL1 
In addition, the C3882S mutation was included into the MLL1 somatic cancer mutants 
R3841W, R3864C and S3865F, to examine if these mutations influence the substrate 
specificity of MLL1. Reduction of the automethylation signal was detected for MLL1 
R3841W and MLL1 S3865F, whereas automethylation could not be removed for MLL1 
R3864C. When the newly introduced cysteine 3864 (resulting from the R3864C mutation) 
was exchanged against glutamine, a loss of automethylation was observed. This result 
indicated that Cys3864 was a new point of automethylation in the MLL1 R3864C mutant. 
Similar to MLL1 wildtype, the H3 methylation was weaker for all MLL1 C3882S proteins 
compared to the methylation with the MLL1 protein variants without C to S mutation. 
Interestingly, the automethylation signal was comparable between MLL1 R3864C and MLL1 
R3864C/C3882S, whereas the H3 methylation was weaker with MLL1 R3864C/C3882S. This 
result supports the hypothesis that the serine induces an opening of the structure and H3 
cannot be properly aligned into the active pocket of MLL1. The influence of the CS mutation 
on the interaction with the complex partners was further investigated for the cancer mutants as 
well, but same as with wildtype MLL1 no change was observed. 
In the next step, MLL1 R3841W/C3882S and MLL1 S3865F/C3882S were used to screen the 
MLL1 specific non-histone targets in presence or in absence of WRA. Both proteins with or 
without complex partners methylated the same targets as MLL1 wildtype. While the target 
preference of MLL1 S3865F was similar to MLL1 wildtype, MLL1 R3841W/C3882S 
behaved differently with H3 or NHT in presence of WRA. A reduction on H3 methylation 
was observed, but methylation of TICRR and ZNF862 was increased in the presence of 
WRA. Also in presence of complex partners stronger automethylation of MLL1 R3841W was 
observed, although H3 methylation was reduced. It seems that the interaction of WRA and 
MLL1 R3841W inhibits the binding or methylation of H3. The mechanism of this inhibition 
has to be further investigated. 
For one of the new MLL1 substrates a biological role has been already reported (Kumagai et 
al. 2010). TICRR, also known as Treslin, interacts with TopBP1 and regulates the initiation of 
DNA replication in vertebrates. Perhaps, TICRR also has a role in the transcriptional 
regulation of genes involved in hematopoiesis and development. Moreover, it is striking that 
DNA replication initiation is also regulated by chromatin modifications and it is known that 
open chromatin replicates early and heterochromatin replicates late. About the zinc finger 
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protein ZNF862 not much is known. It is maybe involved in transcriptional regulation and 
may support MLL1 in its function. To get further insights into the biological roles of these 
two novel MLL1 substrates, cellular studies have to be performed. For example, it needs to be 
investigated if the methylated residue 1017 is involved in the biological functions of TICRR, 
and also if MLL1 inhibitors would affect TICRR. 
5.6. The substrate specificity analysis of MLL3 
A substrate specificity profile analysis was performed with MLL3 methyltransferase as well 
to discover its substrate recognition motif. Since the MLL3 protein is dependent on WRA to 
achieve detectable methyltransferase activity, peptide array analysis was performed with 
MLL3 in presence of complex partners. MLL3-WRA recognized the template H3 (1-15) 
residues from A1 to T6 with a sequence recognition motif of A(ILFP)-R(L)-T(AILMFYV)-
K-Q(NHM)-T(AQEILSV). MLL3-WRA is highly specific at position -2, which is in 
agreement with the crystal structure of MLL3-RA in complex with cofactor product AdoHcy 
and the H3 peptide (Li et al. 2016). Beside the canonical arginine, it weakly accepts leucine at 
this place. At position -3, MLL3-WRA prefers hydrophobic residues, whereas at position +1 
glutamine can be exchanged by asparagine, histidine and methionine without loss of activity. 
Although MLL1 and MLL3 belong to the same PKMT family, differences were observed in 
their specificity profiles (Table 3). 
Table 3: The substrate recognition preference of MLL1 and MLL3-WRA 
Position -3
A1 
-2
R2 
-1
T3 
0
K4 
+1
Q5 
+2
T6 
+3
A7 
+4
R8 
MLL1 
Preference 
PRFWY R ILFWY K RHMFWY IVAC X CY 
MLL3-
WRA 
Preference 
ILFP L AILMFYV K NHM AQEILSV X X 
First of all, MLL1 recognizes a longer sequence than MLL3. A big difference was detected at 
position +4, where MLL1 is highly specific towards arginine, cysteine or tyrosine, while 
MLL3-WRA accepts all 20 natural amino acids. Nevertheless, the complex partners may 
change the specificity of MLL1, so that differences between the specificity profile arrays of 
MLL1 and MLL3-WRA has to be regarded as preliminary observation and further analysis is 
necessary, for example using the MLL1-WRA complex. Using Scansite, 42 potential novel 
non-histone MLL3 substrates were identified and 24 of them were methylated at the peptide 
level. One of the methylated non-histone targets was ZNF862, which was already identified 
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for MLL1. This indicates that overlapping targets of both enzymes exist despite slight 
differences in the recognition motifs were identified. 10 methylated peptides were selected, 
and the corresponding proteins cloned, overexpressed and purified. Out of these ten proteins, 
four non-histone targets were selected for the first round of methylation experiments by 
MLL3-WRA, but none of them was methylated. The remaining 6 targets still have to be 
tested for methylation. This finding illustrates that methylation at peptide level cannot always 
predict methylation at protein level. One reason for this is that peptides synthesized on a 
cellulose membrane are unfolded and easy to access for enzymes. In contrast, proteins are 
folded and the target site can be located inside of the protein and thereby prevent methylation. 
Another possibility is that MLL3 may need the target lysine residue next to N-terminal end, 
which is not the case in a protein. Further experiments are necessary to identify possible 
targets for MLL3-WRA. Moreover, cellular experiments on methylation of ZNF862 would be 
interesting as it is common for MLL1 and MLL3-WRA. In future, a detailed comparison of 
the substrate specificity arrays between MLL1 and MLL3 is necessary to find more common 
and differential targets. 
5.7. Investigation of the somatic cancer mutations of MLL1 and MLL3 
With the improvement of genome-wide sequencing strategies, several somatic mutations in 
PKMTs were detected in cancer tissues. For many PKMTs (EZH2, GLP, NSD2) it was shown 
that somatic cancer mutations influence their enzymatic properties and change the chromatin 
modification patterns introduced by these enzymes (Kudithipudi & Jeltsch 2014). In principle, 
somatic cancer mutations can lead to gain-of-function or loss-of-function effects. Non-sense 
or frameshifts in the coding region of genes generally lead to loss-of-function effect which 
can be understood on the background of the function of the normal gene product. Missense 
mutations can also lead to loss of enzymatic activity by the disruption of critical enzymatic 
functions. This was illustrated by the MLL3 N4848S mutant in this thesis. N4848 is located in 
the NHXC motif in the AdoMet binding pocket of MLL3. The hydrogen bond between 
asparagine and the cofactor is affected after exchange of asparagine against serine, which 
explains loss of activity. 
In contrast, gain-of-function effects can influence different overall enzymatic properties of 
PKMTs, like their activity, product pattern or substrate specificity. The understanding of gain-
of-function mutations, therefore, requires detailed investigations of affected proteins and in 
particular of each specific mutation. Better understanding of the effects of somatic cancer 
mutations in PKMTs will help to understand the role of PKMTs in carcinogenesis and provide 
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foundations for the development of tumor specific therapies. Somatic cancer mutations can 
influence the methylation level preference of PKMTs, which was already discovered for 
EZH2 (Morin et al. 2010; Sneeringer et al. 2010; Yap et al. 2011). EZH2 is the catalytic 
subunit of the PRC2 complex and it mainly introduces H3K27me1 and –me2 in unmethylated 
substrates. It is most frequently mutated at Y641, which is associated with a change in the 
substrate preference and increased H3K27 trimethylation levels (see 1.10). It was observed 
here, that in a similar manner the MLL3 Y4884C mutation converts the MLL3 enzyme from a 
monomethyltransferase to a trimethyltransferase. Y4884 is located in the aromatic cage of 
MLL3 and represents the well-known Phe/Tyr switch position. The tyrosine residue forms a 
hydrogen bond with the ε-amino group of lysine and prevents trimethylation of H3K4. After 
the exchange of tyrosine against Cys, the rotation of the lysine ε-carbon-nitrogen bond is 
possible and further methyl groups can be transferred on the lysine. In addition, the Tyr to 
Cys exchange increases the size of the active site pocket, allowing to reach higher 
methylation states. For several PKMTs it was reported that similar mutations of aromatic cage 
residues affect the substrate preference and product pattern (Collins et al. 2005). The change 
of the methylation pattern of MLL3 may influence the expression of tumor suppressor genes 
or oncogenes and thereby could play a role in carcinogenesis. 
Additionally, somatic cancer mutations may alter the regulation of PKMTs. This was 
illustrated by two somatic cancer mutants in MLL1 which are no longer regulated by WRA. 
MLL1 R3841W and MLL1 R3864C are both hyperactive in isolated form but reduced 
activity was observed when complex partners were added. R3864 is located in the SET-I 
region of MLL1, whereas R3841 is located in the SET-N region and forms a main-chain H-
bond to AdoMet. Both mutants, R3864C and R3841W, were fully active without complex 
partners, which suggest that these missense mutations induce conformational changes from 
the open conformation into a more closed and more active conformation. Interestingly, the 
addition of complex partners inhibits the methyltransferase activity, likely because an inactive 
conformation is adopted. Changes in the conformation of MLL1 R3841W compared to MLL1 
wildtype were already observed with circular dichroism measurements. Altogether, these 
results indicate that somatic cancer mutations can influence conserved regulatory mechanisms 
of PKMTs. This result was further supported by studying the inhibitory effect of the MM-102 
MLL1 inhibitor. The MM-102 drug is a specific MLL1 inhibitor that mimics the GSARAE 
residues in the WIN motif of MLL1 and disrupts the interaction between MLL1 and WDR5 
(Karatas et al. 2013). Enzymatic inhibition was detected for MLL1 wildtype and MLL1 
S3865F. No effect was observed for MLL1 R3841W and MLL1 R3864C. This is in 
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agreement with the discovery that the enzymatic activities of these two enzymes are not 
regulated by the complex partners anymore. For MLL1 wildtype it was shown that MM-102 
leads to reduced expression of MLL1 target genes, like HoxA9 and Meis-1, in leukemia cell 
lines. The data obtained in this study clearly demonstrate that MM-102 has no inhibitory 
effect when R3864C and R3841W mutations are present in MLL1 proteins. This indicates 
that MM-102 cannot be used as therapeutic drug in cancers with these MLL1 mutations. 
Consequently, somatic cancer mutants have to be analyzed in detail to develop personalized 
therapeutic strategies. 
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6. Conclusion 
This chapter presents a summarized conclusion of all projects. A more detailed conclusion of 
individual results is presented in the different publications attached in the appendix or in the 
sections 4.3.1.2.6 and 4.3.2.2.1. 
Up to date 80 PKMTs and hundreds of lysine methylation sites in proteins have been 
identified. However, with the discovery of each single PKMT the following questions appear: 
How is the enzyme regulated and how many methyl groups can be transferred on its 
substrate? How does the enzyme recognize its substrate? Can it methylate further substrates? 
Similarly, the discovery of a lysine methlyation event leads to the following questions: Which 
PKMT can introduce this modification? And what is the biological effect of this methylation 
event?Since aberrant methylation is involved in many diseases, it is important to improve our 
knowledge about each specific PKMT including the investigation of its substrate specificity 
as an important step in the characterization of PKMTs. In this PhD work, substrate peptide 
arrays were used to analyze the detailed substrate preferences of four PKMTs, SUV4-20H1, 
SUV4-20H2, MLL1 and MLL3, revealing the specific influence of each amino acid at every 
position of the substrate peptide on the enzymatic activity. The investigation of the substrate 
preference of SUV4-20H1 and SUV4-20H2 showed that even subtle differences in the 
specificity of these paralogs can be identified with this method. This is important for the 
understanding of the biological roles of closely related gene paralogs in human cells. 
Furthermore, the specificity profile allows the identification of novel substrates for PKMTs 
and supports the connection of methylation sites with the responsible PKMT in a systematic 
fashion. By the identification of novel substrates, additional roles of the enzyme can be 
revealed in various cellular processes. In this thesis, one new protein substrate (CASZ1) was 
identified for SUV4-20H1 and three substrates (CASZ1, OIP5 and CENPU) for SUV4-20H2. 
All three proteins were already known to be methylated at the target lysine residue, but the 
responsible methyltransferase had not been identified. In future, it would be interesting to 
discover these unknown methyltransferases that catalyze the monomethylation of the 
identified NHT, which are further used as substrates for the SUV4-20H enzymes. In this 
respect, comparison between the surrounding sequences of the target lysine residues and the 
substrate preference of different methyltransferases will offer initial insight into suitable 
enzymes. Perhaps, SUV4-20H enzymes are forming complexes with the unknown 
monomethyltransferases, which work together to regulate different regulatory pathways. As 
already concluded in 4.3.1.2.6, two novel protein substrates have been identified. One of 
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them, TICRR interacts with TopBP1 and regulates the initiation of DNA replication in 
vertebrates. In general, methylation of target substrates can influence their function, 
interaction, properties and localization. It would be interesting to analyze, if the methylation 
of TICRR influences its interaction with TopBP1 and thereby affect its function in cells. 
Furthermore, it would be worth to study if novel interaction partners can be identified, which 
may lead to unknown regulatory mechanisms in cells.
The knowledge of the substrate preference of PKMTs can help to identify problematic 
assignments between enzyme and reported target sites in the literature and by this guide 
further work to confirm or disprove described PKMT substrates. The uncovering of wrong 
methylation events is very important, because lysine methylation signaling is involved in the 
regulation of many biological processes. Misinterpretation of lysine methylation processes 
can have various effects on follow-up studies, including misleading therapeutic strategies, 
since methylation reactions are often involved in diseases.  
To advance the understanding of PKMTs it is also important to analyze their product and 
substrate specificity. In PKMTs, the substrate binding site and cofactor binding site are 
situated on opposite surfaces of the catalytic SET domain, connected through a hydrophobic 
tunnel. The product and substrate specificity of a PKMT is dependent on the polarity, shape 
and geometry of this channel. SET8, for example, is a monomethyltransferase using 
unmethylated H4K20 as substrate. It contains a tyrosine residue in the active pocket that 
limits the enzyme to the transfer of one single methyl group. In comparison, in this thesis it 
was shown that SUV4-20H enzymes transfer one methyl group on monomethylated H4K20 in 
vitro. SUV4-20H enzymes contain a serine residue instead of the tyrosine in their active 
pocket. Serine is smaller than tyrosine and therefore a monomethylated substrate better fits 
into the well-defined hydrophobic pocket. Similar to tyrosine, serine also forms a hydrogen 
bond with the target lysine Nε that limits the rotation of the amino group and hinders the 
transfer of a second methyl group. 
The MLL protein family is another example illustrating the importance of the structural 
arrangement of the active pocket for the enzymatic activity. In comparison to other highly 
active SET domain containing proteins, the orientation of the SET-I helix is different in MLL 
proteins. The binding of the complex partners, WDR5, RBBP5 and ASH2L reorients the 
SET-I region and completes the lysine binding channel, which strongly stimulates the 
methyltransferase activity.  
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In recent years several somatic cancer mutations located in the SET domain of PKMTs were 
discovered, which were reported to play an important role in carcinogenesis. The exchange of 
single amino acids can cause a reduction or complete loss of the enzymatic activity, but it can 
also change the product and substrate specificity or important regulatory mechanisms of the 
PKMT, which are necessary for the optimal methyltransferase activity. For example, I 
discovered one MLL1 mutant which was active without the complex members and one MLL3 
mutant which introduces trimethylation at H3K4, where the wildtype MLL3 only generates 
monomethylation. But, why these somatic mutations transform cells into malignancies? 
Changes in the enzymatic properties can affect multiple pathways in cells. For the 
development of successful cancer treatment, the first step is to understand the effects of 
somatic cancer mutations on the enzymatic properties, which was done in the present thesis. 
In the second step, the cellular effects of somatic cancer mutations have to be analyzed. Only 
when the altered regulatory mechanisms are known and understood, one can fight against it 
and develop precise cancer treatment. Inhibitor studies in this thesis with somatic cancer 
mutants indicated, that some compounds which are highly active with wildtype PKMTs are 
no longer able to inhibit mutants. Therefore, it is important to investigate the effect of each 
specific somatic cancer mutant in detail for the development of mutation specific therapeutic 
strategies. 
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Table 4: List of potential novel non-histone targets identified in Scansite search using the recognition motif of MLL1.  
The predicted target lysine is labeled in red 
Swiss 
Prot. 
Nr. 
Original name Name Sequence Protein-length 
MW 
(kDa) 
Target K 
position 
A3 Q9BR61 ACBD6_HUMAN  ACBD6 = Acyl-CoA-binding domain-containing protein 6 LYLYARYKQVKVGNC 282 31 73 
A4 O00767 ACOD_HUMAN  SCD = Acyl-CoA desaturase AAILARIKRTGDGNY 359 42 349 
A5 Q96LA8 ANM6_HUMAN PRMT6 = Protein arginine N-
methyltransferase 6 SVLHARTKWLKEGGL 375 42 178 
A6 O15085 ARHGB_HUMAN  ARHGEF11 = Rho guanine 
nucleotide exchange factor 11 QIHDYRTKRTLGLGS 1522 168 422 
A7 P35613 BASI_HUMAN  BSG = Basigin LTRAPRVKWVRAQAV 385 42 126 
A8 Q8TDC3 BRSK1_HUMAN  BRSK1 = Serine/threonine-protein kinase BRSK1 SGPSRRFKRVVETIQ 778 85 703 
A9 Q8IWQ3 BRSK2_HUMAN BRSK2 = Serine/threonine-protein kinase BRSK2 SGPSRRFKRVVETIQ 736 82 623 
A10 Q7L1Q6 BZW1_HUMAN  
BZW1 = Basic leucine zipper 
and W2 domain-containing 
protein 1 
NKLIRRYKYLEKGFE 419 48 231 
A11 Q9Y6E2 BZW2_HUMAN  BZW2 = Basic leucine zipper 2 domain-containing protein 2 NKLIRRYKYLEKAFE 419 48 123 
A12 P11586 C1TC_HUMAN MTHFD1= C-1-tetrahydrofolate 
synthase, cytoplasmic DIQIRRLKRLGIEKT 935 102 498 
A13 Q5T3J3 CA103_HUMAN 
LRIF1 = Ligand-dependent 
nuclear receptor-interacting 
factor 1 
DEKIRRLKQVLREKE 769 85 749 
A14 Q9H159 CAD19_HUMAN  CDH19 = Cadherin-19 NELGPRFKRLACMFG 772 87 759 
A15 P55286 CADH8_HUMAN CDH8= Cadherin-8 SDWGPRFKRLGELYS 799 88 784 
A16 A6NFT4 CC42B_HUMAN CCDC42B = Coiled-coil domain-containing protein 42B ARLQRRLKRLEPCAR 308 36 138 
A17 P22674 CCNO_HUMAN CCNO= Cyclin-O EVHPPRVKQLLALCC 350 38 198 
A18 P20273 CD22_HUMAN  CD22= B-cell receptor CD22 LKLQRRWKRTQSQQG 847 95 713 
A19 Q03188 CENPC_HUMAN CENPC1= Centromere protein C 1 TPNVRRTKRTRLKPL 943 107 742 
A20 Q52M58 CN177_HUMAN 
C14orf177 =Putative 
uncharacterized protein 
C14orf177 
FCATPRFKQLFKGTV 125 14 112 
A21 Q2M3C6 CO027_HUMAN C15orf27= Transmembrane protein C15orf27 MLRIWRVKRVIDAYV 531 58 213 
B1 Q7Z2Z1 CO042_HUMAN TICRR= Treslin LRRSPRIKQLSFSRT 1910 211 1019 
B2 O15263 DEFB2_HUMAN DEFB4A= Beta-defensin 4A VFCPRRYKQIGTCGL 64 7 48 
B3 Q6QHC5 DEGS2_HUMAN  
DEGS2 = Sphingolipid delta(4)-
desaturase/C4-hydroxylase 
DES2 
LGPYARVKRVYRLAK 323 37 313 
B4 Q16760 DGKD_HUMAN  DGKD= Diacylglycerol kinase delta VKFLRRFKQLLNPAQ 1214 135 343 
B5 Q86XP1 DGKH_HUMAN  DGKH= Diacylglycerol kinase 
eta VKFLRRFKQLLNPAQ 1220 135 354 
B6 Q9P265 DIP2B_HUMAN DIP2B= Disco-interacting protein 2 homolog B FKGWPRLKWVVTDSK 1576 171 486 
B7 O95672 ECEL1_HUMAN ECEL1= Endothelin-converting 
enzyme-like 1 EHPLPRLKYTHDQLF 775 88 704 
B8 Q14156 EFR3A_HUMAN  EFR3A =Protein EFR3 homolog A SALRPRYKRLVDNIF 821 92.924 17 
B9 Q9Y2G0 EFR3B_HUMAN EFR3B= Protein EFR3 homolog B GALRPRYKRLVDNIF 817 92 16 
B10 Q14674 ESPL1_HUMAN ESPL1= Separin ARQAPRLKYLIGAAP 2120 233 2103 
B11 Q9NYZ1 FA18B_HUMAN  FAM18B1= Protein FAM18B1 ALFSFRVKWLAVVIM 205 24 152 
B12 O60258 FGF17_HUMAN FGF17= Fibroblast growth factor 17 SAPTRRTKRTRRPQP 216 25 207 
B13 Q2V2M9 FHOD3_HUMAN FHOD3= FH1/FH2 domain-
containing protein 3 QAREERYKYLEQLAA 1422 159 484 
B14 P42685 FRK_HUMAN  FRK= Tyrosine-protein kinase FRK VVKHYRIKRLDEGGF 505 58 168 
 
B15 Q9BTV5 FSD1_HUMAN  
FSD1= Fibronectin type III and 
SPRY domain-containing 
protein 1 
SFYNARTKQVLHTFK 496 56 441 
B16 A6NG13 GL54D_HUMAN  Glycosyltransferase 54 domain-
containing protein KLASWRIKQVLDFCI 374 44 233 
B17 Q5T7V8 GORAB_HUMAN  GORAB = RAB6-interacting golgin EEELRRLKQTKDPFE 394 45 42 
B18 Q8TAX9 GSDMB_HUMAN GSDMB= Gasdermin-B RVLSYRVKQLVFPNK 411 47 210 
B19 O00219 HAS3_HUMAN  HAS3= Hyaluronan synthase 3 LSLGYRTKYTARSKC 553 63 332 
B20 P51610 HCFC1_HUMAN  HCFC1= Host cell factor 1 VLLQPRWKRVVGWSG 2035 209 20 
B21 Q03164 HRX_HUMAN Histone-lysine N-
methyltransferase MLL ARSNARLKQLSFAGV 3969 432 3707 
C1 Q7Z6Z7 HUWE1_HUMAN HUWE1= E3 ubiquitin-protein ligase HUWE1 PAMAARIKQIKPLLS 4374 482 1047 
C2 Q01113 IL9R_HUMAN  IL9R= Interleukin-9 receptor FKLSPRVKRIFYQNV 521 57 298 
C3 P51617 IRAK1_HUMAN  IRAK1= Interleukin-1 receptor-
associated kinase 1 KTHGARTKYLKDLVE 712 77 432 
C4 P38570 ITAE_HUMAN  ITGAE= Integrin alpha-E LVTSPRTKRTPGPLH 1179 130 61 
C5 O14713 ITBP1_HUMAN ITGB1BP1= Integrin beta-1-binding protein 1 TCAEFRIKYVGAIEK 200 22 66 
C6 Q9UPP5 K1107_HUMAN KIAA1107= Uncharacterized protein KIAA1107 IISLPRVKWTEAALT 1409 156 14 
C7 Q2LD37 K1109_HUMAN KIAA1109= Uncharacterized protein KIAA1109 ETHDARTKRLWFLWP 5005 555 1107 
C8 O15550 KDM6A_HUMAN KDM6A= Lysine-specific demethylase 6A SALAARIKYLQAQLC 1401 154 395 
C9 Q96QE4 LR37B_HUMAN LRRC37B= Leucine-rich repeat-
containing protein 37B LVQLPRLKWVQTTDL 947 106 153 
C10 P22888 LSHR_HUMAN 
LHCGR= Lutropin-
choriogonadotropic hormone 
receptor 
FINLPRLKYLSICNT 699 79 126 
C11 O00453 LST1_HUMAN LST1= Leukocyte-specific transcript 1 protein CWLHRRVKRLERSWA 97 11 39 
C12 Q7L590 MCM10_HUMAN MCM10= Protein MCM10 homolog VPALPRTKRVARTPK 875 98 197 
C13 O60318 MCM3A_HUMAN MCM3AP= 80 kDa MCM3-
associated protein IMRQARVKRTDLDKA 1980 218 623 
C14 P30307 MPIP3_HUMAN CDC25C= M-phase inducer phosphatase 3 NLNRPRLKQVEKFKD 473 53 227 
C15 Q5VT25 MRCKA_HUMAN CDC42BPA= Serine/threonine-protein kinase MRCK alpha EAYERRIKRLEQEKL 1732 197 449 
C16 P35749 MYH11_HUMAN MYH11= Myosin-11 EKGNARVKQLKRQLE 1972 227 1880 
C17 Q9NZM1 MYOF_HUMAN MYOF= Myoferlin FIVWRRFKWVIIGLL 2061 235 2025 
C18 O14594 NCAN_HUMAN NCAN= Neurocan core protein ARDAPRIKWTKVRTA 1321 143 77 
C19 P17677 NEUM_HUMAN GAP43= Neuromodulin LCCMRRTKQVEKNDD 238 25 9 
C20 Q99784 NOE1_HUMAN OLFM1=Noelin CSRDARTKQLRQLLE 485 55 92 
C21 Q6IF63 O52W1_HUMAN OR52W1= Olfactory receptor 52W1 LIYGARTKQIRDRLL 320 34 303 
D1 Q8IXS6 PALM2_HUMAN PALM2= Paralemmin-2 EEDEFRVKQLEDNIQ 379 42 80 
D2 Q9NPG4 PCD12_HUMAN PCDH12=Protocadherin-12 ELGHFRLKRTNGNTY 1184 129 403 
D3 Q96GW7 PGCB_HUMAN BCAN= Brevican core protein VLGSPRVKWTFLSRG 911 99 78 
D4 Q13371 PHLP_HUMAN PDCL= Phosducin-like protein INDWRRFKQLETEQR 301 34 70 
D5 P11086 PNMT_HUMAN PNMT= Phenylethanolamine N-
methyltransferase RQLRARVKRVLPIDV 282 31 152 
D6 O43900 PRIC3_HUMAN PRICKLE3= Prickle-like protein 3 PGEKYRIKQLLHQLP 615 69 130 
D7 Q09MP3 R51A2_HUMAN RAD51AP2= RAD51-associated protein 2 LSRKARIKQLHPYLK 1159 134 1141 
D8 Q96S59 RANB9_HUMAN RANBP9= Ran-binding protein 9 KELQRRLKRLYPAVD 729 78 152 
D9 Q86WA9 S2611_HUMAN 
SLC26A11= Sodium-
independent sulfate anion 
transporter 
FRTLWRVKRLDLLPL 606 65 431 
 
D10 P78381 S35A2_HUMAN SLC35A2= UDP-galactose translocator SAAHRRLKYISLAVL 396 41 36 
D11 Q96H72 S39AD_HUMAN SLC39A13= Zinc transporter ZIP13 EAGAWRLKQLLSFAL 371 39 107 
D12 Q9UHD8 SEPT9_HUMAN SEPT9= Septin-9 HFEAYRVKRLNEGSS 586 65 563 
D13 A8K8P3 SFI1_HUMAN SFI1= Protein SFI1 homolog YTQKRRYKQLLQARA 1242 148 470 
D14 Q9Y5B9 SP16H_HUMAN SUPT16H= FACT complex 
subunit SPT16 DAYYRRVKRLYSNWR 1047 120 15 
D15 Q9Y5Y6 ST14_HUMAN ST14= Suppressor of tumorigenicity 14 protein GVQERRLKRIISHPF 855 95 695 
D16 P47897 SYQ_HUMAN QARS= Glutamine--tRNA ligase DPVAYRVKYTPHHRT 775 88 421 
D17 A6NC51 T150B_HUMAN TMEM150B= Transmembrane protein 150B QLLLWRLKRLPQPGA 233 26 141 
D18 Q9NYW4 TA2R5_HUMAN TAS2R5= Taste receptor type 2 
member 5 IMGIPRVKQTCQKIL 299 35 280 
D19 O95759 TBCD8_HUMAN TBC1D8= TBC1 domain family 
member 8 EALLARLKQVHANHP 1140 131 392 
D20 Q3YBR2 TBRG1_HUMAN TBRG1= Transforming growth factor beta regulator 1 QNEKYRLKYLRLRKA 411 45 37 
D21 Q96BS2 TESC_HUMAN TESC= Calcineurin B homologous protein 3 EQLHRRFKQLSGDQP 214 25 33 
E1 Q6NT04 TIGD7_HUMAN TIGD7= Tigger transposable 
element-derived protein 7 CKRLYRWKQLEESL 549 63 345 
E2 O94876 TMCC1_HUMAN TMCC1= Transmembrane and 
coiled-coil domains protein 1 KQQAARIKQVFEKKN 653 72 278 
E3 Q96QT4 TRPM7_HUMAN 
TRPM7= Transient receptor 
potential cation channel 
subfamily M member 7 
ELHPRIKQLLGKGL 1865 213 153 
E4 Q92574 TSC1_HUMAN TSC1= Hamartin ELDPRRWKRLETHDV 1164 130 248 
E5 Q5VYS8 TUT7_HUMAN ZCCHC6= Terminal 
uridylyltransferase 7 SAIDPRVKYLCYTMK 1495 171 1145 
E6 O75631 UPK3A_HUMAN UPK3A= Uroplakin-3a AATEYRFKYVLVNMS 287 31 165 
E7 Q502W6 VWA3B_HUMAN VWA3B= von Willebrand factor A domain-containing protein 3B ARIRRRIKWLQDGSQ 1294 146 491 
E8 Q64LD2 WDR25_HUMAN WDR25= WD repeat-containing protein 25 PLA AARFKQVKLSRN 544 60 135 
E9 A8MVM7 YD021_HUMAN Putative uncharacterized protein ENSP00000382790 NLAIARLKRTEFKRL 634 73 293 
E10 P49750 YLPM1_HUMAN YLPM1= YLP motif-containing protein 1 PEEDARLKQLQAAAA 1951 220 381 
E11 O96006 ZBED1_HUMAN ZBED1= Zinc finger BED domain-containing protein 1 TFLDPRYKRLPFLSA 694 78 480 
E12 P15822 ZEP1_HUMAN HIVEP1= Zinc finger protein 40 MPRTKQIHPR NL 2718 297 5 
E13 Q63HK3 ZKSC2_HUMAN 
ZKSCAN2= Zinc finger protein 
with KRAB and SCAN domains 
2 
MIPVPRLKRIAISAK 967 111 448 
E14 Q9UBW7 ZMYM2_HUMAN ZMYM2= Zinc finger MYM-type protein 2 EDYLWRIKQLGSHSP 1377 155 1215 
E15 Q8TD17 ZN398_HUMAN ZNF398= Zinc finger protein 398 CGRSFRYKQTLKDHL 642 71 579 
E16 O60290 ZN862_HUMAN ZNF862= Zinc finger protein 862 GDGPRRIKRTYRPRS 1169 132 457 
 

Table 5: List of potential novel non-histone targets identified in Scansite search using the recognition motif of MLL3-WRA. 
The predicted target lysine is labeled in red 
 
Swiss 
Prot. 
Nr. 
Original name Name Sequence Protein-length 
Mw 
(kDa) 
Target K 
position 
A3 Q12873 CHD3_HUMAN  Chromodomain-helicase-DNA-binding protein 3 DGPVRTKKLKRGRPG 2000 227 345 
A4 P15336 ATF2_HUMAN  Cyclic AMP-dependent transcription factor ATF-2 PDEKRRKFLERNRAA 505 55 357 
A5 Q02930 CREB5_HUMAN  Cyclic AMP-responsive 
element-binding protein 5 PDERRRKFLERNRAA 508 57 380 
A6 Q8WYP5 ELYS_HUMAN  Protein ELYS DKQLRIKHVRRVRGR 2266 253 1933 
A7 Q56NI9 ESCO_HUMAN N-acetyltransferase ESCO2 FRLKRRKRIARRLVD 601 68 547 
A8 Q8IZT9 FAM9C_HUMAN  Protein FAM9C EIKNRIKNVLRTTQL 166 19 100 
A9 Q6QHK4 FIGLA_HUMAN  Factor in the germline alpha KERERIKNLNRGFAR 219 24 79 
A10 P41235 HNF4A_HUMAN  Hepatocyte nuclear factor 4-
alpha CRYCRLKKCFRAGMK 474 53 118 
A11 Q92551 IP6K1_HUMAN Inositol hexakisphosphate kinase 1 REQPRRKHSRRSLHR 441 50 116 
A12 P78413 IRX4_HUMAN Iroquois-class homeodomain protein IRX-4 DSGTRRKNATRETTS 519 54 147 
A13 P78412 IRX6_HUMAN  Iroquois-class homeodomain protein IRX-6 SGAGRRKNATRETTS 446 48 151 
A14 P41743 KPCI_HUMAN  Protein kinase C iota type VLLVRLKKTDRIYAM 596 68 274/275 
A15 Q07954 LRP1_HUMAN Prolow-density lipoprotein 
receptor-related protein 1 CNSRRCKKTFRQCSN 4544 505 2568 
A16 Q7L590 MCM10_HUMAN  Protein MCM10 homolog PALPRTKRVARTPKA 875 98 187 
A17 O60318 MCM3A_HUMAN 80 kDa MCM3-associated protein CLGERLKHLERLIRS 1980 218 1951 
A18 O95402 MED26_HUMAN  Mediator of RNA polymerase II transcription subunit 26 ELAKRAKKLLRSWQK 600 66 74/75 
A19 Q8IYA7 MKX_HUMAN  Homeobox protein Mohawk NARRRLKNTVRQPDL 352 39 129 
A20 Q9UMN6 MLL4_HUMAN  Histone-lysine N-
methyltransferase MLL4 VQGPRIKHVCRHAAV 2715 294 879 
A21 Q9NYL2 MLTK_HUMAN Mitogen-activated protein kinase kinase kinase MLT ATLERLKKLERDLSF 800 91 295/296 
B1 Q8IUG5 MY18B_HUMAN  Myosin-XVIIIb VEGLRRKRAQRGQGS 2567 285 2260 
B2 Q6X4W1 NELF_HUMAN  
Nasal embryonic luteinizing 
hormone-releasing hormone 
factor 
ETSGRRKKLERMYSV 530 60 197/198 
B3 Q9H2A3 NGN2_HUMAN  Neurogenin-2 ETVQRIKKTRRLKAN 272 30 110/111 
B4 Q9Y3T9 NOC2L_HUMAN  Nucleolar complex protein 2 homolog PEIKRRKMADRKDED 749 85 652 
B5 Q99743 NPAS2_HUMAN  Neuronal PAS domain-
containing protein 2 DEKDRAKRASRNKSE 824 92 10 
B6 Q13133 NR1H3_HUMAN  Oxysterols receptor LXR-alpha EEQIRLKKLKRQEEE 447 50 177/178 
B7 P10588 NR2F6_HUMAN Nuclear receptor subfamily 2 group F member 6 CQYCRLKKCFRVGMR 404 43 114/115 
B8 Q8WW12 PCNP_HUMAN  PEST proteolytic signal-
containing nuclear protein EAKMRMKNIGRDTPT 178 19 133 
B9 Q8N488 RYBP_HUMAN RING1 and YY1-binding protein TSRPRLKNVDRSTAQ 228 25 149 
B10 Q9NQZ2 SAS10_HUMAN Something about silencing protein 10 GLTPRRKKIDRNPRV 479 55 426/427 
B11 P42229 STA5A_HUMAN  Signal transducer and activator 
of transcription 5A / 5B MSLKRIKRADRRGAE 794 91 425 
B12 Q9UEW8 STK39_HUMAN  STE20/SPS1-related proline-
alanine-rich protein kinase DIAQRAKKVRRVPGS 545 60 362/363 
B13 O75683 SURF6_HUMAN  Surfeit locus protein 6 RQNLRRKKAARAERR 361 41 332/333 
B14 O75478 TAD2A_HUMAN  Transcriptional adapter 2-alpha KERQRRKKIIRDHGL 443 52 222/223 
B15 Q86TJ2 TAD2B_HUMAN Transcriptional adapter 2-beta KERQRRKNIARDYNL 420 49 220 
B16 Q17RP2 TIGD6_HUMAN  Tigger transposable element-derived protein 6 QVDARMKRAERRILL 521 59 273 
 
B17 Q8IY57 YAF2_HUMAN YY1-associated factor 2 KTRPRLKNVDRSSAQ 180 20 106 
B18 P51786 ZN157_HUMAN  Zinc finger protein 157 TGFVRRKRTPRGDKN 506 58 153 
B19 Q86UD4 ZN329_HUMAN Zinc finger protein 329 MRLKMTTRNFPEREV 541 62 4 
B20 O60290 ZN862_HUMAN  Zinc finger protein 862 DGPRRIKRTYRPRSI 1169 132 457 
B21 P17040  ZSC20_HUMAN Zinc finger and SCAN domain-
containing protein 20 QCRYRVKNLLRNYRK 1043 118 381 
C1  
 
Zinc finger and SCAN domain-
containing protein 20 QCRYRFKNLLRSYRK    
C2 Q8IYH5 ZZZ3_HUMAN  ZZ-type zinc finger-containing protein 3 PVLKRIKRCLRSEAP 903 102 117/120 

